Millions of people describe the same paradox: bone-deep exhaustion that does not resolve with more time in bed. The pattern points beyond willpower or sleep hygiene. Emerging research points to mitochondria - the organelles responsible for producing approximately 90% of cellular energy - as a central driver. When mitochondrial adenosine triphosphate production breaks down, the deficit directly undermines the brain's ability to generate and maintain deep sleep, with downstream consequences for cognitive function, metabolic health, and biological aging.

This article covers the experience of unrefreshing sleep and persistent fatigue from a mitochondrial perspective - what the research shows, how mitochondrial fatigue differs from ordinary tiredness, and what testing exists.

Subscribe now

Why Doesn't Rest Fix Mitochondrial Fatigue?

Rest restores adenosine triphosphate only when the mitochondrial machinery is functional. In ME/CFS participants, adenosine triphosphate profile testing reveals near-complete impairment of mitochondrial respiration - five biochemical factors that correlate directly with illness severity. Sleep triggers an adenosine triphosphate surge in wake-active brain regions, but that surge depends on intact oxidative phosphorylation. When oxidative phosphorylation is impaired, more hours in bed do not translate to more cellular energy.

The assumption behind "just get more sleep" is that the energy-production machinery works and needs time to run. A 2009 study by Myhill, Booth, and McLaren-Howard directly challenged that assumption. The researchers recruited 71 individuals with chronic fatigue syndrome and 53 healthy controls, then measured five biochemical factors related to mitochondrial adenosine triphosphate production and transport. The correlation between mitochondrial impairment severity and illness severity (measured by the Bell Ability Scale) reached P<0.001. Only one of 71 CFS participants' results overlapped with the normal control range - giving the test near-complete discriminatory power in this cohort (Myhill et al., 2009).

That finding establishes the cellular deficit, but why does sleep not correct it? A 2010 study by Dworak and colleagues demonstrated the mechanism: sleep triggers a region-specific adenosine triphosphate surge in wake-active brain areas, including the basal forebrain and frontal cortex. The magnitude of that surge correlates with non-rapid eye movement delta activity - the deepest phase of restorative sleep. Sleep deprivation fully prevents the surge (Dworak et al., 2010). The restorative function of sleep is the adenosine triphosphate recharge. If mitochondria cannot execute oxidative phosphorylation efficiently, the sleep-triggered adenosine triphosphate surge is blunted or absent, meaning subjective rest occurs without the cellular restitution that makes rest feel restorative.

A 2025 Nature study by Sarnataro and colleagues provided evidence that these findings extend to the fundamental physiology of sleep pressure. Using single-cell transcriptomics in Drosophila sleep-control neurons, the researchers found that genes upregulated after sleep deprivation encoded "alexclusively proteins with roles in mitochondrial respiration and ATP synthesis" (Sarnataro et al., 2025). This was a fruit fly study, so direct translation to human sleep regulation requires further showation, but the conserved mitochondrial physiology is notable. Sleep deprivation stressd mitochondrial morphology - reducing size, elongation, and branching - in these neurons, consistent with a self-reinforcing trap documented by Zhang and colleagues in a 2024 review of the bidirectional sleep-mitochondria stress loop (Zhang et al., 2024).

What Does Mitochondrial Fatigue Feel Like Compared to Normal Tiredness?

Normal tiredness resolves predictably with adequate sleep - one or two restorative sleep periods and you feel restored. Mitochondrial fatigue does not follow that pattern. It persists through weekends, vacations, and extended rest. Proteomic analysis of ME/CFS participants reveals 99 differentially expressed proteins in immune cells, with notable enrichment in mitochondrial energy production pathways, and even subjective sleep complaints without measurable sleep reduction activate mitochondrial stress pathways.

The distinction between ordinary sleep-debt tiredness and mitochondrial energy impairment matters because the two conditions require fundamentally different responses. A 2020 proteomic study by Sweetman and colleagues used SWATH-MS (Sequential Window Acquisition of all Theoretical Mass Spectra) to profile peripheral blood mononuclear cells from 11 ME/CFS participants and 9 age- and sex-matched healthy controls. Nine of eleven ME/CFS participants clustered distinctly from all controls in unsupervised proteomic analysis. Comparative analysis identified 99 differentially expressed proteins, with notable enrichment mapping to mitochondrial energy production and oxidative stress pathways (Sweetman et al., 2020). The proteomic signature of cellular energy impairment is visible in a standard blood draw.

A separate 2020 study added an unexpected dimension. Martucci and colleagues enrolled post-menopausal women classified with either objective insomnia (showed by actigraphy showing sleep efficiency below 85%) or paradoxical insomnia (reported sleep complaints with normal sleep efficiency on actigraphy). Both groups showed the same altered levels of the mitokines FGF21 and Humanin - mitochondrial stress markers - compared to age-matched controls. No difference existed between the objective and paradoxical insomnia groups on any mitochondrial stress marker (Martucci et al., 2020). Even the perception of poor sleep activates mitochondrial stress responses, making "it's all in your head" biologically inaccurate.

The recognizable pattern of mitochondrial fatigue includes post-exertional malaise (lowerning after modest activity), cognitive impairment disproportionate to sleep reduction, and morning fatigue identical to bedtime fatigue. A 2014 mechanistic review by Morris and Maes explained the connection - pro-inflammatory cytokines including TNF-alpha, combined with oxidative and nitrosative stress, may inhibit electron transport chain activity, reducing adenosine triphosphate output (Morris & Maes, 2014). Inflammation common in chronic conditions drives the energy-production impairment responsible for persistent exhaustion.

Does Unrefreshing Sleep Mean Your Mitochondria Are Underperforming?

Unrefreshing sleep is a hallmark of mitochondrial impairment, not merely poor sleep hygiene. A 2025 Nature study in Drosophila demonstrated that mitochondrial respiration dynamics directly generate sleep pressure - the biological drive to sleep. When mitochondria fragment and lose respiratory capacity, the sleep-control circuitry cannot properly calibrate sleep depth, and the result is sleep that does not restore cellular energy even when duration appears adequate.

Subscribe now

The 2025 Nature study by Sarnataro and colleagues represents the strongest evidence to date that mitochondrial function is inseparable from sleep regulation - though importantly, this work was conducted in fruit flies ( Drosophila ), where sleep-control neurons can be precisely manipulated. Using optogenetics and adenosine triphosphate sensors in sleep-control neurons, the researchers demonstrated that preventing mitochondrial fission increased sleep duration, while inducing mitochondrial fission decreased sleep duration. Installing an artificial electron-overflow mechanism that dissipated excess electron pressure from the respiratory chain relieved sleep pressure without actual sleep - showing that mitochondrial electron transport chain status is itself the sleep-regulatory mechanism in this model. The authors concluded that "sleep may be an inescapable consequence of aerobic metabolism" (Sarnataro et al., 2025). Whether these findings translate directly to mammalian sleep regulation remains to be shown, but the underlying mitochondrial physiology is conserved across species.

A 2025 NIH review by Syed and colleagues identified a molecular driver of the energy impairment in humans: WASF3 (Wiskott-Aldrich syndrome protein family member 3). Under endoplasmic reticulum stress, WASF3 is overproduced and localizes to mitochondria, where it physically disrupts the assembly of respiratory supercomplexes III and IV, directly blocking oxidative phosphorylation. Simultaneously, WASF3 promotes actin polymerization, which further suppresses mitochondrial respiration while upregulating glycolysis - a metabolic change that may support short-term immune activation but leads to chronic energy deficiency when sustained. The resulting impairment of oxidative phosphorylation reduces cellular adenosine triphosphate generation (Syed et al., 2025).

The vicious cycle involves multiple reinforcing mechanisms. Sleep deprivation fragments mitochondria. Fragmented mitochondria impair cellular energy production and may disrupt melatonin synthesis - pineal gland melatonin production depends on mitochondrial energy supply and is sensitive to oxidative stress (Zhang et al., 2024). Each disrupted night compounds the cellular stress from the previous one. A 2024 study by Davinelli and colleagues identified an additional arm of the cycle: sleep restriction increases cellular availability of Cul3, a component of the NRF2 ubiquitination complex. Increased Cul3 sequesters NRF2 - the master regulator of antioxidant gene expression - and prevents NRF2 from activating antioxidant genes including HO-1, NQO1, and glutathione-synthesizing enzymes (Davinelli et al., 2024). With NRF2 suppressed, the cellular defense against oxidative stress from malfunctioning mitochondria is removed, accelerating the deterioration.

Can Mitochondrial Impairment Be Measured or Tested?

Mitochondrial impairment can be measured through several approaches, though accessibility varies. The adenosine triphosphate profile test used in ME/CFS research quantifies five factors of mitochondrial respiration from a blood sample. Muscle biopsy with high-resolution respirometry provides direct tissue-level evidence. Proteomic profiling of blood cells can identify mitochondrial protein signatures.

The adenosine triphosphate profile test developed in the Myhill 2009 study measures five biochemical parameters from a blood sample: adenosine triphosphate concentration, the ratio of adenosine triphosphate available with endogenous magnesium, oxidative phosphorylation recycling efficiency, and two measures of adenosine triphosphate transport across the mitochondrial membrane. In the study cohort, near-complete separation between chronic fatigue syndrome participants and controls made the test a reliable discriminator of mitochondrial energy impairment (Myhill et al., 2009). Specialized laboratories offer this testing.

For direct tissue-level evidence, a 2024 cross-sectional study by Bizjak and colleagues compared skeletal muscle mitochondria across three groups: 15 post-COVID syndrome participants, 15 chronic fatigue syndrome participants, and 13 healthy controls, using both electron microscopy and high-resolution respirometry. The findings revealed mechanistically distinct conditions: chronic fatigue syndrome participants showed more severe morphological degradation - degraded cristae and structural disorganization consistent with long-term cellular stress - while post-COVID syndrome participants showed reduced Complex I oxidative phosphorylation capacity with better-preserved mitochondrial structure (Bizjak et al., 2024). The distinction matters because these conditions converge on fatigue as a shared outcome but may require different measurement and measurement approaches.

A review by Filler and colleagues examined 25 studies and identified coenzyme Q10 as the consistently dysregulated mitochondrial marker across fatigue conditions studied, while carnitine abnormalities were frequently reported though with variable patterns. Low coenzyme Q10 correlated with fatigue severity whenever measured, and carnitine abnormalities were reported in every study that investigated carnitine, though the specific impairments varied across studies (Filler et al., 2014). Both are commercially available blood tests that provide indirect but accessible evidence of mitochondrial status.

What is available now includes organic acids testing, coenzyme Q10 and carnitine levels, and specialized adenosine triphosphate profiles through select laboratories. Blood-based proteomic profiling - where 9 of 11 ME/CFS participants clustered distinctly from all controls (Sweetman et al., 2020) - and high-resolution respirometry remain primarily research tools, but adoption is expanding.

Mitochondrial impairment rarely acts alone. Blood sugar instability, cortisol rhythm disruption, hormonal changes, and inflammation each compound the energy deficit - and many people dealing with unrefreshing sleep have more than one of these causes active simultaneously. The pattern you are experiencing might be primarily mitochondrial, primarily metabolic, or a combination that requires a different approach than targeting any single cause.

Find out which causes might be driving your 3am wakeups ->

Why Am I So Tired But My Body Will Not Let Me Sleep?

Your body may be registering cellular energy deficit as fatigue while simultaneously not generating the mitochondrial-driven processes required to initiate and sustain deep sleep. The 2025 Nature Drosophila study on sleep pressure demonstrated that mitochondrial respiration dynamics are the molecular mechanism generating the drive to sleep in that model organism - when mitochondrial respiration dynamics are impaired, the fatigue experience and the sleep-initiating process become decoupled.

During normal waking hours, adenosine builds as a byproduct of adenosine triphosphate consumption and drives sleep pressure - the increasing urge to sleep that builds throughout the day. This process depends on functional mitochondrial adenosine triphosphate cycling. When mitochondria are stressd, adenosine-mediated sleep drive may be blunted even as subjective exhaustion intensifies (Sarnataro et al., 2025 - shown in Drosophila ; human showation pending). The sensation of being "wired but tired" reflects this decoupling: the body's energy-sensing pathways register depletion, but the sleep-initiating circuitry does not receive the mitochondrial-driven processes required to consolidate restorative sleep.

Can Chronic Fatigue Syndrome Be Caused by Mitochondrial Patterns?

Multiple lines of evidence support mitochondrial impairment as a core feature of ME/CFS. The 2025 NIH review identifies WASF3 protein overproduction as a molecular driver that blocks oxidative phosphorylation supercomplexes III and IV. Proteomic studies find 99 differentially expressed proteins, with notable enrichment in mitochondrial pathways, in ME/CFS participant blood cells.

Whether mitochondrial impairment is the initiating cause of ME/CFS or a downstream consequence of immune activation remains an active research question, but the energy deficit is measurable and consistent across study cohorts (Syed et al., 2025). Chronic fatigue syndrome and post-COVID fatigue show distinct mitochondrial pathology at the tissue level. In the 2024 biopsy study by Bizjak and colleagues, chronic fatigue syndrome participants showed more severe structural degradation of mitochondrial cristae, while post-COVID participants showed more functional impairment of Complex I oxidative phosphorylation with better-preserved morphology (Bizjak et al., 2024). The distinction suggests these conditions may require different approaches despite sharing fatigue as their defining experience.

Can Poor Sleep Create a Cycle That Makes Fatigue Progressively Lower?

Yes - the research supports a bidirectional vicious cycle. Sleep deprivation stresses mitochondrial morphology. The resulting mitochondrial impairment then disrupts melatonin synthesis, which is required for initiating and maintaining restorative sleep. Each disrupted night compounds the cellular stress from the previous one.

The NRF2 suppression mechanism identified by Davinelli and colleagues adds a third arm to the cycle beyond the direct sleep-mitochondria-sleep loop. Sleep restriction blocks the master antioxidant regulator NRF2 through increased Cul3-mediated ubiquitination, removing cellular protection against oxidative stress from malfunctioning mitochondria (Davinelli et al., 2024). Oxidative stress further degrades mitochondrial DNA and membrane integrity, which further impairs sleep architecture - a compounding deterioration that does not self-correct without targeted support.

Subscribe now

What Is Unrefreshing Sleep and What Causes It?

Unrefreshing sleep describes the experience of sleeping for an adequate number of hours but waking without the expected restoration of energy and alertness. Research shows unrefreshing sleep can occur even when objective sleep measurements appear normal. In the 2020 Martucci study, women reporting unrefreshing sleep with normal sleep efficiency showed the same mitochondrial stress markers - altered FGF21 and Humanin - as women with objectively showed insomnia.

The Dworak 2010 finding that sleep's restorative function depends on an adenosine triphosphate surge in wake-active brain regions during non-rapid eye movement sleep provides the mechanistic explanation: if the mitochondrial machinery is impaired, the adenosine triphosphate surge is blunted (Dworak et al., 2010). The electroencephalogram may look normal while cellular restoration does not occur. The disconnect between sleep duration and sleep quality in mitochondrial impairment explains why standard sleep guidance - consistent bedtime, dark room, limited screens - does not resolve the fatigue. Those steps optimize sleep conditions but do not repair the energy-production machinery that makes sleep restorative (Martucci et al., 2020).

References

• Bizjak, D. A., Ohmayer, B., Buhl, J. L., Schneider, E. M., Walther, P., Calzia, E., Jerg, A., Matits, L., & Steinacker, J. M. (2024). Functional and Morphological Differences of Muscle Mitochondria in Chronic Fatigue Syndrome and Post-COVID Syndrome. International Journal of Molecular Sciences , 25(3), 1675.

• Davinelli, S., Medoro, A., Savino, R., & Scapagnini, G. (2024). Sleep and Oxidative Stress: Current Perspectives on the Role of NRF2. Cellular and Molecular Neurobiology , 44(1), 52.

• Dworak, M., McCarley, R. W., Kim, T., Kalinchuk, A. V., & Basheer, R. (2010). Sleep and brain energy levels: ATP changes during sleep. The Journal of Neuroscience , 30(26), 9007-9016.

• Filler, K., Lyon, D., Bennett, J., McCain, N., Elswick, R., Lukkahatai, N., & Saligan, L. N. (2014). Association of Mitochondrial impairment and Fatigue: A Review of the Literature. BBA Clinical , 1, 12-23.

• Martucci, M., Conte, M., Ostan, R., Chiariello, A., Miele, F., Franceschi, C., Salvioli, S., Santoro, A., & Provini, F. (2020). Both objective and paradoxical insomnia elicit a stress response involving mitokine production. Aging , 12(11), 10497-10505.

• Morris, G., & Maes, M. (2014). Mitochondrial impairments in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metabolic Brain Disease , 29(1), 19-36.

• Myhill, S., Booth, N. E., & McLaren-Howard, J. (2009). Chronic fatigue syndrome and mitochondrial impairment. International Journal of Clinical and Experimental Medicine , 2(1), 1-16.

• Sarnataro, R., Velasco, C. D., Monaco, N., Kempf, A., & Miesenbock, G. (2025). Mitochondrial origins of the pressure to sleep. Nature , 645(8081), 722-728.

• Sweetman, E., Kleffmann, T., Edgar, C., de Lange, M., Vallings, R., & Tate, W. P. (2020). A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial impairment. Journal of Translational Medicine , 18(1), 365.

• Syed, A. M., Karius, A. K., Ma, J., Wang, P. Y., & Hwang, P. M. (2025). Mitochondrial impairment in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Physiology (Bethesda, Md.) , 40(4), 0.

• Zhang, W., Liu, D., Yuan, M., & Zhu, L. Q. (2024). The mechanisms of mitochondrial abnormalities that contribute to sleep disorders and related neurodegenerative diseases. Ageing Research Reviews , 97, 102307.

Research supports four evidence-based approaches to raising GABA activity naturally. Exercise - particularly high-intensity interval training - increases cortical GABA by approximately 20%. Yoga showed a trend toward elevated thalamic GABA and correlated with mood improvements in ways that matched-calorie walking did not. Certain gut bacteria (Lactobacillus and Bacteroides species) produce GABA directly, and moderate fermented food intake (roughly 64 - 151 grams per day) showed optimal sleep outcomes in a prospective study of 280 participants. Meditation increases GABA-B-mediated cortical inhibition measurably after a single session.

Whether you want to support GABA function without supplements or combine lifestyle changes with supplementation, there are research-backed approaches that increase GABAergic activity - the activity of GABA, the brain's primary inhibitory neurotransmitter.

Subscribe now

Does Exercise Increase GABA for Better Sleep?

Yes - and the type of exercise matters. High-intensity interval training raised motor cortex GABA by approximately 20% in TMS and MRS studies, while moderate aerobic cycling raised cortical GABA by approximately 7%. A yoga-focused RCT found that yoga showed a trend toward elevated thalamic GABA and was associated with improved mood and anxiety scores in ways that calorie-matched walking was not.

Does Exercise Type Affect How Much GABA Increases?

Yes. A 2024 review of TMS and MRS studies found that high-intensity interval training raised motor cortex GABA by roughly 20%, while moderate aerobic cycling raised cortical GABA by roughly 7%. The intensity of the exercise appears to determine the magnitude of the GABAergic response.

A 2024 review in Neuroscience Insights synthesized evidence from transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy (MRS) studies - two methods that assess GABA activity and concentration in living human brains (Novak et al., 2024).

Aging progressively reduces cortical GABA concentrations and weakens inhibitory interneuron efficiency. Exercise partially reverses this decline, with effects observed in the motor cortex, prefrontal cortex, and cerebellum. The review concludes that exercise-induced brain health improvements are partly driven by recovery of inhibitory GABAergic processes - not solely by BDNF-mediated neuroplasticity.

Does Yoga Increase GABA Differently Than Other Exercise?

In a 12-week RCT, yoga showed a trend toward elevated thalamic GABA and correlated with improved mood and lower anxiety. Calorie-matched walking did not show the same pattern, suggesting that yoga's non-aerobic components - breath control, postures, and focused attention - may contribute to the effect independently of energy expenditure.

Streeter et al. (2010) assigned 34 healthy participants to either yoga (n=19) or walking (n=15) in metabolically matched 60-minute sessions, three times per week. Thalamic GABA was measured by MRS before and after sessions.

The yoga group showed greater improvement in mood (Exercise-Induced Feeling Inventory) and greater decreases in state anxiety compared to the walking group - despite equivalent caloric expenditure. Increases in thalamic GABA correlated with improvements in mood and reductions in anxiety.

Because both groups burned the same calories, the observed pattern in GABA changes was not explained by an aerobic fitness effect. Yoga's non-aerobic components - breath control, postures, and focused attention - may have contributed to the differential GABA trend.

Why does thalamic GABA matter for sleep?

The thalamus is the brain's relay hub for sleep-wake transitions. Higher thalamic GABA means stronger inhibitory gating of arousal input - the sensory and cognitive activity that can keep you awake or wake you up during the night.

Does Exercise Timing Affect the GABA Benefit for Sleep?

Late afternoon exercise (roughly 4 - 6 pm) allows cortisol to normalize before bed. Late-night exercise can elevate cortisol and counteract the GABA benefit by maintaining sympathetic arousal - elevated heart rate, heightened alertness - into the sleep onset window.

Exercise raises cortisol acutely - a normal physiological response. Late afternoon exercise gives cortisol several hours to return to baseline before bed. Late-night exercise can keep cortisol elevated through the sleep onset window, maintaining sympathetic arousal and reducing the calming effect of GABA increases.

Schedule higher-intensity exercise earlier in the day. Reserve gentler movement (yoga, stretching) for the evening.

Can Gut Health Affect GABA and Sleep?

Your gut microbiome produces GABA directly. Bacteroides species are the primary gut GABA producers, and their abundance inversely correlates with markers of brain connectivity disruption in depression. Lactobacillus strains also produce GABA and have been shown in placebo-controlled human trials to reduce rumination and cognitive reactivity to sad mood. Fermented foods - which are rich in these bacteria - showed a dose-response relationship with sleep quality, with moderate intake (roughly 64 - 151 grams per day) as the optimal range.

Which Gut Bacteria Produce GABA?

Bacteroides species are the primary gut GABA producers. Lactobacillus strains - particularly L. plantarum and L. brevis - also produce GABA via the glutamate decarboxylase (GAD) pathway. Both genera have documented effects on mood and brain connectivity in human studies.

Strandwitz et al. (2019) in Nature Microbiology identified gut bacterial species that produce and consume GABA, establishing a direct microbial route of influence on the brain's primary inhibitory neurotransmitter.

In 23 individuals with major depressive disorder, fecal Bacteroides abundance inversely correlated with frontal brain connectivity disruption (Pearson r = -0.67, p = 0.0005) - higher gut Bacteroides was associated with more intact brain connectivity.

A 2025 review in Brain mapped the full picture: Lactobacillus and Bacteroides species produce GABA via the glutamate decarboxylase (GAD) enzyme encoded by gadA/B genes. Since GABA is unlikely to cross the blood-brain barrier, microbially produced GABA almost certainly influences brain function indirectly through three mechanisms: activation of GABA-A receptors in the enteric nervous system, GABA-A receptor activation in the immune system, and exosome-mediated signaling (Belelli et al., 2025).

Can Probiotics with GABA-Producing Bacteria Improve Mood and Sleep?

In a double-blind, placebo-controlled crossover trial of 87 adults, a probiotic combining L. plantarum and L. brevis reduced rumination (p = 0.006) and cognitive reactivity to negative mood (p = 0.034). Gut colonization was confirmed in responders, connecting the bacterial presence to the psychological benefit.

Casertano et al. (2024) tested a probiotic formulation containing two GABA-producing Lactobacillus strains - L. plantarum and L. brevis - in 87 healthy adults.

The probiotic group showed reduced rumination (p = 0.006) and lower cognitive reactivity to sad mood (p = 0.034) compared to placebo. Gut microbiome analysis confirmed colonization in responders, with increased abundance of L. plantarum (p = 0.009) and L. brevis (p = 0.004).

Fecal GABA concentrations did not correlate with psychological outcomes, suggesting the mood benefits may be mediated through indirect gut-brain pathways rather than direct GABA absorption into the bloodstream.

How Much Fermented Food Supports GABA and Sleep?

A prospective cohort study of 280 participants found that moderate fermented food intake (the second tercile, roughly 64 - 151 grams per day) was associated with the best sleep quality under stress. Below that range, the benefit was smaller. Above it, sleep quality worsened - suggesting a dose threshold rather than a "more is better" relationship.

Dobielska et al. (2025) followed 280 medical students through an exam period, measuring fermented food intake and sleep quality using the Pittsburgh Sleep Quality Index (PSQI).

The relationship was V-shaped, not linear. Students in the moderate-consumption group (second tercile, roughly 64 - 151g/day) had the best sleep quality, with a mean PSQI of 5.13. The lowest consumption group scored 5.73, and the highest consumption group scored 6.17 - worse than both moderate and low intake.

The proposed mechanism: short-chain fatty acids and serotonin produced by fermented food-associated microorganisms, along with HPA axis modulation, may buffer stress-induced sleep disruption at moderate doses but have counterproductive effects at high doses.

Fermented food sources containing GABA-producing Lactobacillus strains include kimchi, yogurt, kefir, sauerkraut, and miso. The moderate-intake range corresponds to roughly one serving per day - a portion of yogurt, a side of kimchi, or a glass of kefir.

Does Meditation Increase GABA?

A TMS study in 70 participants found that a single meditation session increased GABA-B-mediated cortical inhibition in experienced meditators compared to controls (p = 0.02). This is the first receptor-type finding linking meditation to GABA: the effect was at GABA-B receptors, suggesting meditation supports a different but complementary form of GABAergic inhibition than exercise or neurosteroids.

How Does Meditation Affect GABA-B Receptors?

Guglietti et al. (2013) measured the cortical silent period - a TMS parameter that reflects GABA-B receptor-mediated inhibition - in 35 experienced meditators versus 35 matched controls before and after a single 60-minute meditation session. Meditators showed increased GABA-B cortical inhibition; controls watching television did not.

After a 60-minute meditation session, meditators showed increased cortical silent period duration (p = 0.02), reflecting enhanced GABA-B receptor-mediated inhibitory neurotransmission. Controls who watched television for the same duration showed no change.

Short intracortical inhibition (SICI) - which reflects GABA-A receptor activity - showed no between-group differences. Meditation enhanced GABA-B (slow, metabotropic) inhibition without affecting GABA-A (fast, ionotropic) inhibition.

Why Does the GABA-B vs. GABA-A Distinction Matter for Sleep?

Sleep maintenance relies more on GABA-A receptor activity (fast, ionotropic inhibition), while meditation enhances GABA-B activity (slow, metabotropic inhibition). The two receptor types serve complementary roles - meditation may prepare the GABAergic environment for sleep without directly targeting the same receptor as sleep-maintenance GABA mechanisms.

GABA-A receptors produce fast, direct inhibition - they open ion channels that rapidly reduce neural firing. GABA-B receptors produce slower, modulatory inhibition through intracellular cascades that reduce excitability over longer timeframes.

The two are complementary. Meditation may prepare the brain's inhibitory environment for sleep by enhancing GABA-B tone, while GABA-A activity handles the moment-to-moment work of maintaining sleep continuity through the night.

To be precise: this is one study with one measure. It does not mean "meditation cures insomnia." It means meditation produces a measurable, receptor-dependent GABAergic effect in a single session - through a complementary pathway to sleep-maintenance GABA mechanisms.

Supporting GABA naturally through exercise, diet, and gut health addresses one mechanism behind nighttime waking. But testosterone decline, cortisol disruption, metabolic instability, and circadian misalignment might also be contributing - and in many cases, more than one cause is at work.

Find out which causes might be driving your 3am wakeups ->

Frequently Asked Questions

• How Do You Increase GABA Levels Naturally?

• Can Magnesium Improve GABA and Help You Stay Asleep?

• Can GABA Supplements Help Nighttime Anxiety?

Read more

I’ve been writing online for 3 years now.

Over those three years, one idea has become more important to me:

You are the person who lives in your body every day.

You often notice day-to-day changes before they show up in a single appointment or lab snapshot.

Your energy changes.

Your sleep changes.

A meal sits differently.

Stress lands differently than it used to.

A short appointment may not capture all of that. Your daily knowledge matters.

The goal is to bring better context to your conversations with doctors and experts: sharper questions, your own patterns, and the data of your daily life.

That is what I mean by becoming the CEO of your health.

For this 3-year reader thank-you, the regular paid annual subscription to The Longevity Vault is available at a lifetime reader rate of $99/year.

The regular annual rate is $247. Monthly access is $35, or $420/year if paid month to month.

This July 4th weekend, the lifetime annual reader rate is $99/year, and that rate stays on annual renewals.

Join at the lifetime annual rate

The reader rate is available through Sunday, July 5, 2026, and closes at midnight ET as Monday, July 6 begins.

Use it as a place to keep building the context that helps you take the next step for your health: sleep, labs, metabolic health, hormones, brain health, and longevity.

Warmly,
Kat

P.S. Thank you for reading, replying, and bringing the questions that make this work sharper.

When the body cannot break down histamine efficiently, histamine-related arousal pathways may stay more active during the sleep period - and standard sleep supplements that interact with mast cell pathways may be insufficient when histamine load or mast cell activation is part of the sleep problem. Addressing histamine clearance may improve sleep quality, daytime energy, and cognitive function over time when histamine burden is one of the active contributors. This article covers how diamine oxidase enzyme deficiency connects to insomnia, why common sleep remedies may be incomplete when histamine is elevated, what the research shows about histamine-targeted approaches, and how mast cell activation extends that disruption.

Subscribe now

What Is Histamine Intolerance and How Does It Affect Sleep

Histamine intolerance is not an allergy - it is a reduced capacity to break down histamine, typically from low diamine oxidase (DAO) enzyme activity. When histamine accumulates faster than the body can break it down, histamine-related arousal pathways may remain active during the sleep period. In a prospective prevalence study of 167 adults with insomnia-related symptoms, 82.6% carried genetic variants associated with DAO deficiency, and 88% reported difficulty staying asleep as their primary complaint (Lopez Garcia et al., 2024).

Histamine is one of the brain's primary wake-promoting neurotransmitters. Histaminergic neurons in the tuberomammillary nucleus (TMN) - a small cluster in the posterior hypothalamus - fire during wakefulness and stop firing during sleep (Thakkar, 2011). When histamine-related signaling remains elevated, that wakefulness drive may make sleep more fragmented.

The enzyme responsible for breaking down histamine in the gut and bloodstream is diamine oxidase (DAO). Genetic variants in the AOC1 gene - the gene encoding DAO - reduce the body's capacity to degrade histamine from food and from endogenous mast cell release. In a 2024 prospective prevalence study of 167 adults presenting with insomnia-related symptoms, 82.6% carried AOC1 variants associated with DAO deficiency. Among those with higher genetic burden (four or more single nucleotide polymorphisms), rates of sleep maintenance problems and early morning awakening were elevated compared to those with fewer variants (Lopez Garcia et al., 2024).

The insomnia pattern in histamine intolerance tends to look different from stress-related or circadian-related sleep problems. The predominant complaint in Lopez Garcia's cohort was difficulty staying asleep (88%), followed by difficulty falling asleep (60.5%). That maintenance-dominant pattern - falling asleep at a reasonable time but waking repeatedly or too early - is consistent with histamine-related arousal contributing to wakefulness during the second half of the night.

Beyond sleep, histamine intolerance produces a constellation of overlapping presentations. In a study of 77 individuals with histamine intolerance, Tamasi and Kalabay (2025) documented respiratory issues in 95%, bloating in 94%, headache in 91%, fatigue in 83%, and postprandial drowsiness in 81%. The drowsiness-fatigue combination is often misattributed to poor sleep alone, when histamine excess may be contributing to both daytime fatigue and nighttime waking.

One reason histamine intolerance goes unrecognized for so long: the presentations vary from episode to episode in the same person after similar exposures, making it difficult to identify a pattern.

What Is the Diamine Oxidase Enzyme and How Does It Affect Sleep

Diamine oxidase (DAO) is the primary enzyme responsible for breaking down histamine in the gut and bloodstream. When DAO activity is low - from genetic variants, gut inflammation, or certain medications - histamine from food and mast cell release accumulates instead of being cleared. A 2026 randomized controlled trial found that DAO supplementation improved sleep quality measures, and participants using melatonin had greater insomnia severity improvement with DAO than with placebo (Ferrer-Garcia et al., 2026).

DAO is produced in the intestinal mucosa. Its primary job is to degrade histamine before it enters the bloodstream. When DAO activity is sufficient, dietary histamine - from aged cheeses, fermented foods, cured meats, alcohol - gets broken down in the gut. When DAO activity is low, that histamine passes into circulation and adds to whatever histamine the body is already producing through mast cell activity.

Several factors reduce DAO activity beyond genetics. Gut inflammation can damage the intestinal cells that produce DAO. Alcohol inhibits DAO directly. Certain medications - including some NSAIDs and antiarrhythmics - also reduce DAO function (Hrubisko et al., 2021).

When a genetic predisposition toward low DAO combines with any of these factors, nighttime histamine burden may remain elevated during the hours when wakefulness-promoting histamine signaling should be lower.

Subscribe now

The connection between DAO support and sleep improvement has recent evidence. In a 2026 randomized, double-blind, placebo-controlled trial, 101 adults with insomnia and confirmed AOC1 gene variants received either DAO supplementation or placebo for 28 days. The DAO group showed improvements in Pittsburgh Sleep Quality Index scores - including sleep efficiency and reduced sleep medication use - compared to placebo. Among participants who were also taking melatonin, insomnia severity improvements were greater in the DAO group at both day 7 and day 28 (Ferrer-Garcia et al., 2026).

The DAO-plus-melatonin finding matters. For people whose insomnia involves histamine accumulation, melatonin alone may be insufficient because it does not address the histamine excess. Adding DAO enzyme support may reduce one wake-promoting input while melatonin supports circadian-driven sleep onset. Without addressing the histamine burden first, melatonin is working against a wakefulness drive it was not designed to override.

The mechanistic link is biologically plausible but should be stated carefully: histamine promotes wakefulness through H1 receptor activation in the TMN, while DAO primarily reduces peripheral histamine burden. Histaminergic neurons fire exclusively during wakefulness and cease firing during NREM and REM sleep (Thakkar, 2011). Reducing circulating histamine - whether through DAO supplementation, dietary histamine reduction, or both - may reduce one contributor to nighttime arousal in people whose sleep disruption is histamine-related.

Can Mast Cell Activation Syndrome Cause Insomnia

Yes. In a study comparing 553 individuals with MCAS to 558 controls, those with MCAS had elevated rates of severe chronic insomnia across both sexes. MCAS involves pathological mast cell degranulation that releases not only histamine but serotonin, cytokines, and prostaglandins - creating compounding sleep disruption that extends beyond what antihistamines alone can address (Weinstock et al., 2025).

Mast cell activation syndrome (MCAS) is a condition in which mast cells degranulate inappropriately - releasing inflammatory mediators without a true allergic trigger. Where histamine intolerance involves impaired breakdown of histamine, MCAS involves excessive production and release of histamine alongside many other mediators.

MCAS carries a heavy sleep burden. Weinstock et al. (2025) surveyed 553 individuals with MCAS and 558 controls and found that insomnia was among the neuropsychiatric conditions elevated in MCAS across both sexes. Women with MCAS reported higher rates in 18 of 19 neurologic categories and all 14 psychiatric categories; men reported higher rates in 17 of 19 neurologic categories and 8 of 14 psychiatric categories. When those with MCAS rated the effectiveness of various approaches for their neuropsychiatric presentations, antihistamines received a rating of 6.3 out of 10 - outperforming benzodiazepines at 5.6 out of 10. That finding is relevant, but it should be read as patient-reported neuropsychiatric relief overall rather than an insomnia-specific drug comparison.

MCAS also creates sleep disruption through pathways beyond histamine alone. Weinstock et al. (2020) found that 40.8% of individuals with MCAS had restless legs syndrome, compared to 12.9% of spouse controls. In women with MCAS, there was an odds ratio of 6.7 compared with the general U.S. female population. Restless legs syndrome disrupts sleep onset and sleep maintenance independently - meaning people with MCAS can face both histamine-driven early awakening and movement-related sleep fragmentation at the same time.

The compounding nature of MCAS is what distinguishes it from isolated histamine intolerance. When mast cells degranulate, they release histamine, but also prostaglandins, serotonin, cytokines (including TNF-alpha and IL-6), and tryptase. These mediators can influence arousal, pain, inflammation, autonomic tone, and movement-related sleep disruption through different pathways. This is why people with MCAS often describe their insomnia as resistant to every approach they have tried: each remedy addresses one pathway while several others remain active.

Why Do Standard Sleep Remedies Make Histamine Intolerance Worse

Many standard sleep supplements do not address histamine clearance or mast cell mediator release. Melatonin interacts with mast cell pathways and may reduce some inflammatory signaling, but the available evidence does not show that melatonin alone resolves histamine-related insomnia. Fermented supplements and some probiotic formulations may also add histamine or histamine-producing organisms in sensitive individuals.

Melatonin is typically the first supplement people reach for when sleep is disrupted.

Read more

Yes, through a specific metabolic pathway. Gut dysbiosis alters the bacteria that produce short-chain fatty acids and regulate secondary bile acids — two compounds that influence insulin sensitivity and postprandial blood sugar. When this microbial function is disrupted, glycemic variability increases. At night, when the body's glucose regulation is already at its weakest point in the circadian cycle, those swings can trigger the counterregulatory hormone surge — epinephrine, cortisol, glucagon — that wakes you.

Research connecting gut health to sleep has expanded over the past five years, but coverage typically conflates two distinct mechanisms. This article focuses on the metabolic pathway: specific gut bacteria regulate blood sugar stability, and when those bacteria are depleted or imbalanced, the downstream effect is nocturnal glycemic instability. A 2022 study of 550 adults found that gut microbiome functional activity independently predicts individual postprandial glycemic variability across more than 30,000 meals — positioning the gut as a primary blood sugar regulator, not just a digestive organ (Tily et al., 2022).

Chronic nocturnal blood sugar instability may accelerate the insulin resistance progression that underlies metabolic syndrome, type 2 diabetes, and cognitive decline. Understanding whether gut dysbiosis is the upstream driver changes the target: dietary fiber and fermented foods — not carbohydrate restriction alone — become relevant tools.

This article covers how specific gut bacteria influence blood sugar, how poor sleep and gut dysbiosis reinforce each other, and what the evidence shows about restoring microbial balance.

Subscribe now

Which Gut Bacteria Regulate Blood Sugar — and What Happens When They Are Depleted?

Gut bacteria from the Christensenellaceae family correlate positively with both REM sleep duration and lower continuous glucose variability; Enterobacteriaceae show the inverse pattern. In a study of 127 adults with obstructive sleep apnea, dysbiosis of fecal Bacteroides thetaiotaomicron was associated with impaired glucose metabolism in a multi-omics analysis (Chen et al., 2025). When dysbiosis reduces SCFA-producing bacteria, insulin-sensitizing function degrades and glycemic variability increases.

Certain gut bacteria produce short-chain fatty acids — primarily butyrate and propionate — that influence insulin sensitivity. Short-chain fatty acids activate free fatty acid receptors in the gut and stimulate incretin hormone secretion, which modulates insulin release after meals and hepatic glucose output between meals. When the bacteria that produce butyrate and propionate are depleted, this communication chain weakens, and postprandial blood sugar becomes less stable (Withrow et al., 2021).

Arnoriaga-Rodriguez et al. (2023) enrolled 118 participants (60 with obesity, 58 without) and simultaneously measured continuous glucose via a Dexcom G6 monitor for 10 days, sleep architecture via wrist actigraphy, and gut microbiota composition via shotgun metagenomics. Bacteria from the Christensenellaceae family showed positive correlations with REM sleep duration and negative correlations with glucose levels, while Enterobacteriaceae demonstrated the inverse. Glucose variability — measured by standard deviation, coefficient of variation, and interquartile range — was each independently associated with shorter REM sleep duration (beta = -0.350, P < .001). Iron metabolism-related microbial pathways were associated with higher glucose variability and shorter REM, implicating specific metabolic functions in the gut-sleep-glucose relationship.

Chen et al. (2025) took a multi-omics approach in 127 adults with obstructive sleep apnea, integrating serum metabolomics and gut microbiota profiling. Two factors were associated with impaired glucose metabolism in the context of objective daytime sleepiness: dysregulation of serum valine catabolism and dysbiosis of fecal Bacteroides thetaiotaomicron. B. thetaiotaomicron is a polysaccharide fermenter that contributes to short-chain fatty acid production and intestinal barrier function; its dysbiosis may impair the insulin-sensitizing SCFA pathway described above.

An underappreciated distinction exists between compositional dysbiosis — an overall loss of microbial diversity — and functional dysbiosis, a loss of specific metabolite-producing capacity. Romanenko et al. (2025) identified functional metabolite output as more sensitive to circadian and sleep disruption than taxonomic composition alone. Standard 16S sequencing may show a gut community that looks normal by diversity metrics while missing a deficit in SCFA-producing capacity that is already degrading glycemic control.

For the gut-cholesterol side: If your interest in gut health includes LDL-C, ApoB, or high cholesterol despite healthy diet and exercise, The Gut-LDL-C Blueprint walks through the gut-liver side of cholesterol in a self-paced format.

See The Gut-LDL-C Blueprint →

Does Poor Sleep Cause Gut Dysbiosis — or Does Gut Dysbiosis Cause Poor Sleep?

Both. A randomized crossover study in nine normal-weight young men found that two nights of partial sleep restriction measurably altered the Firmicutes-to-Bacteroidetes ratio and reduced postprandial insulin sensitivity — without changing fecal SCFA concentrations (Benedict et al., 2016). In the other direction, a population study of 720 adults found that both night-to-night sleep variability and elevated wake-after-sleep-onset were independently associated with lower gut microbiome richness and diversity (Holzhausen et al., 2024).

Benedict et al. (2016) conducted a randomized crossover study in nine normal-weight young men comparing two nights of partial sleep deprivation (sleep restricted to 2:45-7:00am) versus normal sleep (10:30pm-7:00am). After partial sleep deprivation, the ratio of Firmicutes to Bacteroidetes increased — a compositional change consistently associated with metabolic impairment in the literature. Coriobacteriaceae and Erysipelotrichaceae showed higher relative abundance, while the phylum Tenericutes was reduced (all P < 0.05). Fasting and postprandial insulin sensitivity both decreased following the two-night sleep restriction compared to normal sleep (P < 0.05). Fecal short-chain fatty acid concentrations did not change. The authors noted that the lack of SCFA change suggests compositional changes in specific taxa, rather than broad metabolite-output changes, may be involved in the acute glucometabolic effect.

Two nights. In normal-weight young men. That is how rapidly sleep restriction alters gut composition and glucose handling.

A 2026 meta-analysis by Supasitdikul et al. pooled 20 studies and quantified the effect of sleep deprivation on the gut microbiome across species. Sleep deprivation reduced alpha diversity (Shannon index SMD = -1.27; 95% CI: -2.20 to -0.34) and increased the Firmicutes-to-Bacteroidetes ratio (SMD = 2.60; 95% CI: 1.61 to 3.59). Human studies showed nonsignificant trends in the same direction — the authors attributed this to small sample sizes and heterogeneous sleep deprivation designs rather than a true null effect.

The other direction of the cycle is equally supported. Holzhausen et al. (2024) enrolled 720 adults (mean age 55 years; 58% female) and found that poor self-reported sleep quality was associated with lower gut microbiome richness and alpha diversity. Greater night-to-night variability in sleep duration — not just short sleep — was associated with reduced microbial richness, suggesting sleep irregularity may be a relevant factor in gut microbial composition independent of sleep duration. Higher wake-after-sleep-onset and lower sleep efficiency were both linked to diminished gut microbiome diversity.

Withrow et al. (2021) suggested that disrupted microbial metabolite output may feed back to affect circadian alignment through gut-brain axis communication, while sleep disruption simultaneously degrades the microbial communities that produce those metabolites. Addressing only one side of the cycle — fixing sleep without attending to gut health, or fixing the gut without improving sleep — leaves the reinforcing loop partially intact.

How Does Gut Dysbiosis Produce the Nocturnal Blood Sugar Swings That Cause 3am Waking?

Circadian disruption flattens the normal 24-hour rhythmicity of gut microbial populations, destabilizing the timing of SCFA and secondary bile acid production. This temporal uncoupling compounds at night, when endogenous glucose regulation is already under circadian-dependent modulation. The result is increased nocturnal glycemic variability — drops or spikes sufficient to trigger the counterregulatory hormone cascade (epinephrine, cortisol, glucagon) that produces the abrupt 3am awakening.

Gut bacteria do not produce metabolites at a constant rate. In a well-functioning gut, SCFA and secondary bile acid production follows a circadian rhythm, synchronized with the host's feeding-fasting cycle and hormonal oscillations. Romanenko et al. (2025) reviewed evidence showing that circadian disruption — from rotating work schedules, irregular sleep timing, or chronic sleep deprivation — reduces microbial oscillation rhythmicity and diminishes functional metabolite output. This functional disruption is more sensitive to circadian disturbance than taxonomic composition, meaning standard microbiome sequencing approaches underestimate the metabolic damage.

The body's overnight glucose regulation depends on a circadian-synchronized pattern of incretin hormone activity and insulin secretion. Microbial metabolite timing partly drives this pattern: SCFAs stimulate incretin hormone secretion from intestinal cells, and secondary bile acids activate receptors including FXR in the liver that modulate hepatic glucose output. When microbial metabolite production is temporally uncoupled from the host's circadian schedule, overnight glucose management is impaired — insulin secretion is mistimed relative to hepatic glucose output, and glycemic variability increases during the hours when the body is least equipped to compensate.

The scale of the gut's contribution to glycemic variability is measurable. Tily et al. (2022) analyzed more than 30,000 meals consumed by 550 adults using metatranscriptomic sequencing combined with continuous glucose monitoring. A model incorporating gut microbiome functional activity, anthropometrics, and food macronutrients achieved a Pearson correlation of R = 0.77. Individuals consuming identical meals produced widely different glycemic responses, and the functional state of the gut microbiome explained a large portion of that interpersonal variability. This predictive power may apply overnight as well: two people with the same dinner and the same bedtime may have different overnight glucose trajectories based on their gut microbial functional capacity.

Arnoriaga-Rodriguez et al. (2023) showed the glucose-sleep connection in overnight conditions using 10-day CGM data. Glucose variability metrics — standard deviation, coefficient of variation, interquartile range — each independently correlated with shorter REM sleep duration (beta = -0.350, P < .001). The gut's influence on glycemic stability may contribute to the REM sleep fragmentation associated with glucose variability.

Dos Santos and Galie (2024), in a review of 36 studies, identified shared pathophysiological links between hyperglycemia, insulin resistance, and sleep-disruption-associated gut dysbiosis. The nocturnal glucose swing is both cause and consequence — gut dysbiosis increases glycemic variability, which fragments sleep, which worsens gut dysbiosis, which increases glycemic variability further.

Many people have more than one cause contributing to their sleep disruption. Gut-dysbiosis-driven blood sugar instability may compound with cortisol timing abnormalities, insulin resistance, or circadian misalignment. Identifying which causes might be involved is a useful next step.

Find out which causes might be driving your 3am wakeups →

Does Restoring Gut Bacteria Improve Blood Sugar Stability and Sleep?

Dietary modification targeting gut microbial composition has the strongest evidence for improving both glycemic variability and sleep quality at the same time. A review of 36 studies found that dietary pattern changes, dietary supplementation, and probiotic supplementation all demonstrated capacity to alter microbiota composition while modulating sleep quality metrics and metabolic markers (Dos Santos & Galie, 2024). Dietary modifications showed the strongest evidence. Probiotic evidence is more limited and strain-specific.

Dos Santos and Galie (2024) evaluated three categories of gut-targeted approaches across 36 studies: dietary pattern modification, dietary supplementation (fiber, polyphenols), and probiotic supplementation. All three demonstrated capacity to alter microbiota composition while improving both sleep quality metrics and metabolic markers. Dietary pattern modification — increasing fiber diversity, fermented food consumption, and overall dietary diversity — showed the strongest evidence for modulating both microbial composition and the metabolite output relevant to glycemic stability.

Romanenko et al. (2025) proposed that meal timing optimization aligned with circadian rhythms could realign microbial and host metabolic rhythms and reduce dysbiosis. This proposal is consistent with the circadian uncoupling mechanism: if the gut's metabolite production has become desynchronized from the host's circadian schedule, eating within a consistent window that matches the body's expected feeding period may help re-entrain microbial oscillation patterns. This remains a theoretical framework with supportive preclinical evidence but limited controlled human trial data.

Because gut microbiome functional activity predicts individual postprandial glycemic response at R = 0.77 (Tily et al., 2022), modulating microbial function is a personalized target for blood sugar control. But the specific change needed — which fiber types, what quantity of fermented foods, which probiotic strains — depends on the individual's microbial deficits. A person depleted in butyrate-producing Christensenellaceae faces a different functional deficit than someone with low Bacteroides thetaiotaomicron.

One mechanism that is often conflated with the metabolic pathway but functions separately: gut bacteria are involved in tryptophan metabolism, and tryptophan is the precursor to serotonin and melatonin. Arnoriaga-Rodriguez et al. (2023) found that iron metabolism-related microbial pathways correlated with higher glucose variability and shorter REM — a finding specific to the metabolic gut-sleep pathway, not the tryptophan-melatonin pathway. The melatonin connection is plausible mechanistically, but quantitative data on gut-derived tryptophan's contribution to circulating melatonin in humans is not yet established.

Subscribe now

What the evidence supports as starting points: dietary diversity (a wider range of plant fibers feeding a wider range of microbial communities), regular inclusion of fermented foods (providing both live microbes and substrates), and consistent meal timing aligned with daytime hours. What it does not yet support: specific probiotic strains, fiber doses, or supplement regimens for improving nocturnal glycemic stability.

Frequently Asked Questions

Can Gut Problems Cause Insomnia?

Yes, through at least two pathways. The metabolic pathway — dysbiosis reduces SCFA production, impairs insulin sensitivity, and increases nocturnal glycemic variability — is the mechanism this article covers. A separate inflammatory pathway involves gut permeability and elevated cytokines entering circulation. Both produce sleep fragmentation, but they respond to different approaches.

Benedict et al. (2016) demonstrated that even two nights of partial sleep restriction produced measurable gut compositional changes and insulin sensitivity reduction in normal-weight young men — establishing that the metabolic pathway is rapidly responsive, not a slow-developing condition. The Firmicutes-to-Bacteroidetes change and the postprandial insulin sensitivity decrease appeared within 48 hours, in people with no pre-existing gut or metabolic conditions.

Holzhausen et al. (2024) found in a population of 720 adults that sleep efficiency, wake-after-sleep-onset, and night-to-night sleep variability were each associated with gut microbiome richness — not only in people with identified gut conditions but across a general population. The metabolic pathway is likely relevant when waking correlates with food choices, meal timing, or blood sugar-related sensations (hunger, sweating, racing heart).

What Is the Gut-Brain Axis and How Does It Affect Sleep?

The gut-brain axis is the bidirectional communication network connecting gut microbial communities to brain-based sleep-regulation centers. It functions through three channels: vagal nerve transmission, immune mediators (cytokines), and microbially produced neuroactive compounds including GABA precursors, serotonin precursors, and short-chain fatty acids. From a sleep-metabolic standpoint, the channel with the strongest evidence is SCFA-mediated regulation, which influences insulin secretion and hepatic glucose output — both of which determine overnight blood sugar stability.

Dos Santos and Galie (2024) identified shared gut-brain axis biomarkers across sleep disturbances and metabolic syndrome components including hyperglycemia, dyslipidemia, and central obesity — indicating these are not parallel problems but a common pathophysiological substrate. The gut-brain axis carries the feedback loop described throughout this article: once dysbiosis impairs glycemic stability and fragments sleep, the resulting poor sleep further degrades microbial diversity (Supasitdikul et al., 2026), reinforcing the cycle from both ends.

Does Leaky Gut Cause Sleep Problems?

Gut permeability (commonly called leaky gut) can disrupt sleep, but through a different mechanism than the one this article covers. Increased intestinal permeability allows bacterial endotoxins to enter circulation, triggering immune activation and cytokine-mediated sleep fragmentation — that is the inflammatory pathway. The metabolic pathway covered here (dysbiosis reducing SCFA output, increasing glycemic variability, driving nocturnal waking) is distinct. Both can coexist, but they respond to different approaches.

This distinction matters practically. Someone focusing on the metabolic pathway (improving dietary fiber diversity, fermented food intake, meal timing) may see no improvement if gut permeability is the primary mechanism — and the reverse is equally true. Withrow et al. (2021) reviewed both pathways and described them as running in parallel rather than as the same mechanism. The indicator for the metabolic pathway: 3am waking that correlates with food choices, timing of the last meal, or post-meal blood sugar patterns. The inflammatory pathway tends to be less time-locked to meals.

How Does the Microbiome Affect Melatonin Production?

Gut bacteria are involved in tryptophan metabolism, and tryptophan is the precursor to both serotonin and melatonin. Dysbiosis can reduce tryptophan bioavailability for these pathways. However, the quantitative contribution of gut-derived tryptophan metabolism to circulating melatonin levels is not established by human evidence. The more strongly supported gut-sleep mechanism remains the metabolic pathway: SCFA production influencing insulin sensitivity and glycemic stability.

Arnoriaga-Rodriguez et al. (2023) found that iron metabolism-related microbial pathways correlated with both higher glucose variability and shorter REM sleep — a finding distinct from the tryptophan-melatonin pathway and specific to the metabolic gut-sleep connection. The melatonin connection is plausible mechanistically but should not be used to justify probiotic supplementation for sleep without strain-specific human trial evidence. The glycemic variability evidence base — not the tryptophan-melatonin hypothesis — is where dietary and microbial approaches have the strongest support.

Subscribe now

References

• - Arnoriaga-Rodríguez, M., Leal, Y., Mayneris-Perxachs, J., Pérez-Brocal, V., Moya, A., Ricart, W., Fernández-Balsells, M., & Fernández-Real, J. M. (2023). Gut microbiota composition and functionality are associated with REM sleep duration and continuous glucose levels. The Journal of Clinical Endocrinology and Metabolism, 108(11), 2931-2939.

• - Benedict, C., Vogel, H., Jonas, W., Woting, A., Blaut, M., Schürmann, A., & Cedernaes, J. (2016). Gut microbiota and glucometabolic alterations in response to recurrent partial sleep deprivation in normal-weight young individuals. Molecular Metabolism, 5(12), 1175-1186.

• - Chen, L., Chen, B., Dai, Y., Sun, Q., Wu, J., Zheng, D., Vgontzas, A. N., Tang, X., & Li, Y. (2025). The association of objective daytime sleepiness with impaired glucose metabolism in patients with obstructive sleep apnea: A multi-omics study. Sleep, 48(2), zsae240.

• - Dos Santos, A., & Galié, S. (2024). The microbiota-gut-brain axis in metabolic syndrome and sleep disorders: A systematic review. Nutrients, 16(3), 390.

• - Holzhausen, E. A., Peppard, P. E., Sethi, A. K., Safdar, N., Malecki, K. C., Schultz, A. A., Deblois, C. L., & Hagen, E. W. (2024). Associations of gut microbiome richness and diversity with objective and subjective sleep measures in a population sample. Sleep, 47(3), zsad300.

• - Romanenko, M., Bartsch, M., Piven, L., Hahn, A., & Müller, M. (2025). Gut microbiota and circadian disruption in humans: Is there a rationale for metabolic disorders? Chronobiology International, 42(9), 1244-1264.

• - Supasitdikul, T., Mazariegos, J. R. R., Nhat, N. N., Tung, Y. T., Yang, D. F., Lee, L. J., Gunawan, S. P., & Chen, Y. C. (2026). Sleep deprivation alters gut microbiome diversity and taxonomy: A systematic review and meta-analysis of human and rodent studies. Journal of Sleep Research, 35(2), e70125.

• - Tily, H., Patridge, E., Cai, Y., Gopu, V., Gline, S., Genkin, M., Lindau, H., Sjue, A., Slavov, I., Perlina, A., Klitgord, N., Messier, H., Vuyisich, M., & Banavar, G. (2022). Gut microbiome activity contributes to prediction of individual variation in glycemic response in adults. Diabetes Therapy, 13(1), 89-111.

• - Withrow, D., Bowers, S. J., Depner, C. M., González, A., Reynolds, A. C., & Wright, K. P., Jr. (2021). Sleep and circadian disruption and the gut microbiome-possible links to dysregulated metabolism. Current Opinion in Endocrine and Metabolic Research, 17, 26-37.

Read more

The most powerful evolution in longevity won’t come from AI alone, or from new reimbursement models alone.

It will come from a change in mindset.

Patients are stepping into the role of CEO of their own health.

The driver isn’t distrust. It’s recognition.

We’re the ones living in our bodies every day.

We notice the patterns no one else sees — when energy dips, when sleep gets restless, when stress hits differently, when certain foods don’t sit well, when something feels off before it shows up in a lab.

That is irreplaceable intelligence.

And no 15-minute appointment, no matter how skilled the clinician, can substitute for that level of intimacy.

In this new model, doctors and specialists become expert COOs:

• They bring technical expertise, execution, and deep knowledge

• They help interpret labs, guide treatment, and stress-test decisions

• They bring the medical judgment that keeps strategy grounded

But the patient drives the vision.

The patient sets the goals.

The patient defines what “well” means in the body they live in.

This is what health sovereignty looks like:

• Patients informed enough to ask better questions

• Equipped enough to advocate for prevention as much as treatment

• Grounded enough to integrate multiple expert views into one cohesive strategy

And just as important: knowing how to show up with better tools.

• The tests that help you monitor your own baselines

• The metrics that track energy, sleep, recovery, and resilience

• The questions that reveal when you can take action yourself — and when you need a medical partner

Health sovereignty doesn’t mean doing it all alone.

It means knowing what is yours to own, and where collaboration matters.

And when you show up this way — equipped, curious, prepared, collaborative — you change the dynamic.

You’re no longer a passive recipient of care.

You become the strategist.

You bring lived experience that matters.

You bring the data of your daily life.

You ask questions that can change the course of your treatment.

You become the link between what science can measure and what your body has been trying to tell you.

That’s how lasting healing begins.

Through shared power.

Through informed participation.

Through partnership built on mutual respect.

That’s the bridge — from longevity information to implementation — that more of us need to walk.

So the question is: Are you ready to step into the CEO seat of your health?

—Kat

Yes and no.

Here’s why that matters.

1. Is “sunlight in the eyes” actually good for you?

Your body has a clock inside it.

This clock helps tell you when to feel awake, when to feel sleepy, when to eat, and when many hormones should rise or fall. Light and dark are t…

Read more

Scott Anderson is a scientist and science writer who wrote the bestselling book The Psychobiotic Revolution (from National Ge…

Read more

"I've had this issue for a very long time now where I wake up too early and then drift in and out of restless sleep for the last 1-2 hours of sleep and none of the standard sleep habit tricks help. I will go to bed at around 22:00 and consistently wake up around 3 am, falling in and out of sleep 3-4 times until 5 am with a lot of movement in my sleep causing achiness as well."

They'd tried everything.

Subscribe now

Going to bed earlier just shifted the wake-up to 2am instead of 3am. They'd planned entire days around sleep—timing exercise, sunlight, meals, winding down hours before bed with no screens. Complete caffeine detox. Melatonin. Even prescription sleep aids.

Nothing worked.

Why Standard Sleep Advice Misses the Real Problem

When you've optimized everything about sleep onset but still can't stay asleep past 5-6 hours, you're dealing with something deeper than sleep hygiene. The issue isn't getting to sleep—it's what happens to your sleep architecture in that second half of the night.

Waking up after 5-6 hours and drifting in and out isn't just "light sleep."

It's often a mismatch between your sleep systems and the signals that should sustain deeper stages. After sleep onset, your body's ability to maintain continuous rest depends less on external cues and more on how internal recovery systems behave during those later hours.

For someone focused on longevity, this matters beyond just feeling tired.

Fragmented sleep in the second half of the night disrupts the deeper stages where your brain clears metabolic waste, consolidates memory, and maintains cognitive resilience—the very processes that protect against cognitive decline and preserve mental sharpness as you age.

My Approach: Three Sleep Architecture Disruptions

I used to struggle with this exact pattern.

Sometimes it was falling asleep, other times it was waking up at 2 or 3am and not being able to get back to deep rest. I tried all the standard approaches for years without consistent results.

What finally helped wasn't another sleep hygiene tip.

It came from understanding the underlying mechanisms that govern sleep continuity—specifically what disrupts the transition between sleep stages after that first window.

Here are the three factors I've found most often drive this pattern:

1. Cholinergic–GABAergic Imbalance in REM Initiation

The switch between REM and non-REM sleep is governed by a delicate balance between cholinergic activity (which promotes REM) and GABAergic activity (which promotes deep sleep).

When GABA tone is insufficient—or acetylcholine spikes too early—you may enter REM too soon and too frequently, disrupting the normal sequencing of restorative stages.

This creates a cycle where you get some sleep, but not the sustained deep phases needed for true recovery.

2. Inadequate Daytime Sleep Pressure

Sleep pressure builds through adenosine accumulation during wakefulness, especially with physical exertion and cognitive effort.

If daytime activity is too sedentary or mistimed—such as intense workouts too late in the day—the first half of the night may be deeper, but not long enough to sustain full rest.

Therefore, the issue isn't just what you do before bed, but how you build sleep drive throughout the entire day.

3. Melatonin Offset Timing

Melatonin supplementation likely isn't helping here because it's designed to initiate sleep, not maintain it.

Natural melatonin rises a couple of hours before bedtime, peaks around 2–4 a.m., and stays elevated for most of the night before tapering toward dawn. When evening light delays this curve, melatonin may no longer align with the chosen sleep window — creating instability or awakenings in the early morning hours.

Taking melatonin right at bedtime doesn’t fix this misalignment. Supplemental melatonin creates a short spike that fades within a few hours, often exaggerating the contrast between the first and second half of the night. Instead of supporting sleep continuity, it can reinforce the early-morning drop-off and disrupt transition into subsequent stages.

The Science Behind Sleep Architecture Breakdown

What most people don't realize is that sleep isn't just one continuous state.

Your brain cycles through distinct stages approximately every 90 minutes, with the proportion of deep sleep versus REM changing throughout the night.

In the first half of the night, you get most of your deep sleep—the stage that handles physical recovery and memory consolidation. The second half is when REM sleep becomes more prominent, supporting emotional processing and cognitive function.

When sleep architecture is disrupted, this natural progression breaks down.

Instead of smooth transitions between stages, you get fragmented periods where your brain can't fully commit to either deep sleep or REM, leaving you in that frustrating in-between state of drifting consciousness.

This fragmentation doesn't just affect how rested you feel—it specifically impairs the brain's ability to clear metabolic waste through the glymphatic system, which primarily operates during deeper sleep stages.

For longevity-focused individuals, this represents a critical pathway for maintaining cognitive health over decades.

Moving Beyond Sleep Hygiene

Once I stopped focusing only on sleep onset and started looking at what was disrupting continuity, my sleep became much more stable. The breakthrough came from shifting perspective entirely—instead of asking "How do I fall asleep better?" I started asking "What's preventing my brain from staying in restorative stages?"

The solution wasn't another bedtime routine—it was understanding how sleep pressure, neurotransmitter balance, and circadian timing interact during those critical hours after 3am. This meant tracking not just when I went to bed, but how different daytime activities affected my adenosine buildup. It meant testing whether late afternoon light exposure was shifting my melatonin curve. It meant recognizing that my 6pm workout might be creating the wrong kind of arousal signal at the wrong time.

Most importantly, it meant treating sleep as a biological system with measurable inputs and outputs, rather than something I could willpower my way through.

When I started testing variables systematically—adjusting one factor at a time and measuring sleep continuity rather than just duration—the 3am wake-ups finally started to resolve.

This is the approach behind the sleep intelligence app I am now opening for VIP early access: daily guidance for men 40+ that connects sleep patterns, sleep architecture, and daytime activity to recovery, brain health, and longevity.

Coming to iOS and Android.

VIP early access is open here:

Claim your VIP spot

(Join the waitlist, or forward this with someone you care about who could benefit.)

Warmly,
Kat

References

• Chen, ZK., Dong, H., Liu, CW. et al. A cluster of mesopontine GABAergic neurons suppresses REM sleep and curbs cataplexy. Cell Discov 8, 115 (2022).

• Reiter, R.J.; Sharma, R.; Chuffa, L.G.d.A.; Simko, F.; Dominguez-Rodriguez, A. Mitochondrial Melatonin: Beneficial Effects in Protecting against Heart Failure. Life 2024, 14, 88.

• Sletten TL, Vincenzi S, Redman JR, Lockley SW, Rajaratnam SM. Timing of sleep and its relationship with the endogenous melatonin rhythm. Front Neurol. 2010 Nov 1;1:137.

• Baskett JJ, Broad JB, Wood PC, Duncan JR, Pledger MJ, English J, Arendt J. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing. 2003 Mar;32(2):164-70.

• Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment No. 108. (Prepared by the University of Alberta Evidence-based Practice Center, under Contract No. 290-02-0023.) AHRQ Publication No. 05-E002-2. Rockville, MD: Agency for Healthcare Research and Quality. November 2004.

• Marupuru S, Arku D, Campbell AM, Slack MK, Lee JK. Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Aug 31;11(17):5138.

• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773.

• Fu, K. (2025, June 6). The 3 forms of sleep disruption that shrink your brain—and how to tell if your sleep is actually protecting you from cortical atrophy, brain shrinkage and neurodegeneration. The Longevity Vault.

• Fu, K. (2025, June 12). Melatonin for sleep: Why it often fails—and what to do instead to stay asleep to prevent brain aging, cognitive decline, and toxin buildup at night. The Longevity Vault.

• Lee T, Cho Y, Cha KS, Jung J, Cho J, Kim H, Kim D, Hong J, Lee D, Keum M, Kushida CA, Yoon IY, Kim JW. Accuracy of 11 Wearable, Nearable, and Airable Consumer Sleep Trackers: Prospective Multicenter Validation Study. JMIR Mhealth Uhealth. 2023 Nov 2;11:e50983.

• Robbins, R.; Weaver, M.D.; Sullivan, J.P.; Quan, S.F.; Gilmore, K.; Shaw, S.; Benz, A.; Qadri, S.; Barger, L.K.; Czeisler, C.A.; et al. Accuracy of Three Commercial Wearable Devices for Sleep Tracking in Healthy Adults. Sensors 2024, 24, 6532.

• Cavaillès C, Dintica C, Habes M, Leng Y, Carnethon MR, Yaffe K. Association of Self-Reported Sleep Characteristics With Neuroimaging Markers of Brain Aging Years Later in Middle-Aged Adults. Neurology. 2024 Nov 26;103(10):e209988.

• Kokošová V, Filip P, Kec D, Baláž M. Bidirectional Association Between Sleep and Brain Atrophy in Aging. Front Aging Neurosci. 2021 Dec 8;13:726662.

• Vidal-Pineiro, D., Parker, N., Shin, J. et al. Cellular correlates of cortical thinning throughout the lifespan. Sci Rep 10, 21803 (2020).

• Deantoni, M., Reyt, M., Dourte, M. et al. Circadian rapid eye movement sleep expression is associated with brain microstructural integrity in older adults. Commun Biol 7, 758 (2024).

• Cho G, Mecca AP, Buxton OM, Liu X, Miner B. Lower slow wave sleep and rapid eye-movement sleep are associated with brain atrophy of AD-vulnerable regions. bioRxiv [Preprint]. 2025 Jan 14:2025.01.12.632386.

• Sexton CE, Storsve AB, Walhovd KB, Johansen-Berg H, Fjell AM. Poor sleep quality is associated with increased cortical atrophy in community-dwelling adults. Neurology. 2014 Sep 9;83(11):967-73.

• Lim AS, Fleischman DA, Dawe RJ, Yu L, Arfanakis K, Buchman AS, Bennett DA. Regional Neocortical Gray Matter Structure and Sleep Fragmentation in Older Adults. Sleep. 2016 Jan 1;39(1):227-35.

• A. Shahid et al. (eds.), STOP, THAT and One Hundred Other Sleep Scales

The researchers used large biobank datasets, especially UK Biobank, and compared self-reported sleep duration with 23 biologi…

Read more

That makes sense.

Growth hormone affects muscle, bone, fat metabolism, and tissue repair. But growth hormone also sits inside a larger overnight process that includes sleep depth, brain health and dementia.

In a UK Biobank analysis of 369,711 adults, IGF-1 - the hormone the liver produces in response to growth hormone - tracked hippocampal volume.

Specifically, lower IGF-1 was associated with

• a smaller hippocampus,

• less white matter volume, and

• more white matter lesions.

The study adjusted for sex, age, ethnicity, educational attainment, smoking status, alcohol intake frequency, vegetable and fruit intake, body mass index, hypertension, diabetes, total cholesterol, and C-reactive protein.

In a separate long-term study, adults in the lowest IGF-1 quartile had a 51% higher risk of developing Alzheimer's dementia over 7.4 years.

Growth hormone is also tied to the part of sleep that matters for overnight restoration. The largest growth hormone release of the 24-hour cycle usually occurs during the first 60-90 minutes of sleep, when slow-wave sleep is deepest.

During slow-wave sleep, cerebrospinal fluid movement through the glymphatic pathway increases. Recent human data show that sleep-active clearance helps move amyloid beta and tau (proteins involved in Alzheimer's disease pathology) from brain tissue.

But is more growth hormone better?

In this article we'll discuss:

• what the longevity data supports in relation to growth hormone

• which factors support healthy growth hormone function

• which factors disrupt growth hormone release or reduce IGF-1 ( insulin-like growth factor-1) response

• 9 things you can do today, to improve growth homone function for optimal brain health & longevity without using peptides or exogenous hormones, regardless of your age

Let's get started.

Section 2. The IGF1 (insulin-like growth factor-1) paradox - why longevity data does not support maximizing growth hormone

The assumption behind peptide use is that restoring youthful growth hormone output is desirable.

The longevity data is more nuanced.

Insulin-like growth factor-1 is the primary liver-produced hormone that responds to growth hormone. It carries many of the tissue-level effects associated with growth hormone: muscle protein synthesis, bone density maintenance, and cellular repair.

Large pooled analyses suggest that insulin-like growth factor-1 has a U-shaped association with all-cause mortality.

• At the low end, lower insulin-like growth factor-1 is linked with frailty, sarcopenia, cognitive decline, and bone vulnerability.

• At the high end, higher insulin-like growth factor-1 is linked with proliferative concerns, with acromegaly as the human example of chronic growth hormone and insulin-like growth factor-1 excess.

The longevity target is the middle of the range.

There is also a timing question.

Growth hormone is normally released in pulses, with the largest release tied to early slow-wave sleep.

A single lab value does not show whether growth hormone was released at the expected time, whether insulin-like growth factor-1 stayed in a physiologic range, or whether the tissue response was optimal.

So what affects whether the nightly growth hormone release happens at the right time?

Section 3. Factors that support healthy growth hormone function

1. Sleep depth and continuity

The largest growth hormone release of the day usually occurs during the first episode of slow-wave sleep. In one study of healthy men aged 16-83, slow-wave sleep fell from 18.9% of total sleep time in young adulthood to 3.4% by midlife, while growth hormone release fell in parallel.

What matters is more than total sleep duration. The depth and continuity of the first sleep block determine whether the early sleep-linked growth hormone release has a place to occur.

Sleep fragmentation can reduce the early growth hormone release even when total sleep time looks adequate. Chronic sleep restriction can also move growth hormone release into smaller events later in the sleep period.

Across midlife, the growth hormone change tracks the loss of slow-wave sleep closely.

By the way, if sleep after 40 no longer responds to the usual strategies, I’m opening private early access to my science-backed sleep intelligence app built exclusively for men 40+, coming to iOS and Android.

It is tailored to men’s sleep physiology after 40, including testosterone, growth hormone, and GABA-related changes

Join the waitlist - or share this with someone you care about who could benefit:

Early access VIP watilist

2. Circadian alignment

In the early sleep period, growth hormone-releasing hormone activity is more supportive of release, while somatostatin restraint tends to be lower.

Both circadian timing and sleep onset contribute to growth hormone release. The circadian component means a late or biologically mismatched sleep period can change the size and timing of the release.

Adequate sleep at a mismatched time can still contain slow-wave sleep, but the hormonal context around that sleep is different.

When sleep onset moves across a wide range, the circadian clock has a harder time aligning sleep pressure, melatonin timing, and the growth hormone-releasing hormone/somatostatin balance.

3. Insulin

Growth hormone release is lower when fasting insulin and abdominal visceral fat are higher.

When insulin drops between meals, the pituitary is less exposed to one of the metabolic conditions associated with lower growth hormone release. When insulin stays elevated through frequent eating, late-night intake, or caloric excess, the first deep sleep block begins under a different endocrine state.

Free fatty acids also matter. Abdominal visceral fat can raise free fatty acid delivery to the liver and pituitary, which can further reduce growth hormone release.

4. Testosterone and estrogen

Testosterone and estrogen help shape growth hormone pulse size and the downstream insulin-like growth factor-1 response.

• In men, testosterone can support growth hormone release directly. But the insulin-like growth factor-1 response also depends partly on aromatization to estradiol. When aromatization is blocked, testosterone can still affect growth hormone release, while the insulin-like growth factor-1 response may be smaller.

• In women, estrogen can support growth hormone release by reducing somatostatin tone at the hypothalamus.

In midlife, testosterone function becomes more easily disrupted in men, and estrogen changes through perimenopause and menopause in women.

Section 4. The factors that disrupt healthy growth hormone function

1. Somatostatin affects growth hormone release and timing

Somatostatin is the hypothalamic hormone that suppresses growth hormone release.

It has appeared throughout this article because sleep timing, insulin exposure, cortisol physiology, inflammation, alcohol, and energy state all interact with the balance between growth hormone-releasing hormone and somatostatin.

The human data are more nuanced than the old shorthand. Growth hormone-releasing hormone stimulates release. Somatostatin reduces the size of that release. Ghrelin and related ligands can amplify the pituitary response.

Aging tends to involve

• lower growth hormone-releasing hormone activity,

• altered ghrelin rhythm, and

• higher somatostatin restraint.

That combination can reduce growth hormone pulse size even when the pituitary can still respond.

Read more

GABA — gamma-aminobutyric acid — is one of the brain’s main calming molecules, and many sleep medicines work by boosting its effects. Gut microbes can also make GABA. But whether that gut-made GABA reaches the brain, and whether it matters for sleep, is a question the field is only now begin…

Read more

The circadian rhythm is the body’s internal ~24-hour clock, driven by a molecular feedback loop in the suprachiasmatic nucleus of the hypothalamus. It coordinates sleep-wake timing, hormone release, body temperature, metabolism, and immune function across every organ and tissue.

Your body runs on a clock. The suprachiasmatic nucleus — a pair of small nuclei in the anterior hypothalamus — receives light input through the retinohypothalamic tract and uses that input to synchronize the body’s internal timing to the external light-dark cycle.

The molecular basis of this clock is a transcription-translation feedback loop. The proteins BMAL1 and CLOCK form a heterodimer that activates transcription of the PER and CRY genes. As PER and CRY proteins accumulate, they feed back to inhibit BMAL1/CLOCK activity, suppressing their own transcription. This loop takes approximately 24 hours to complete — and it runs in every cell in the body (Annals of Medicine, 2025).

The suprachiasmatic nucleus is the master pacemaker, but it is not the only clock. Every organ — the liver, gut, kidneys, adrenal glands, skeletal muscle — has its own peripheral clock running the same molecular loop. The suprachiasmatic nucleus synchronizes these peripheral clocks through neural projections, hormones (including cortisol and melatonin), and autonomic nervous output (Albrecht, Neuron, 2012).

When circadian timing is intact, these distributed clocks coordinate: body temperature drops in the evening, melatonin rises, cortisol falls, and the brain transitions from wakefulness into consolidated sleep. When circadian timing breaks down, each of these coordinated outputs can go wrong independently.

The health consequences of circadian disruption extend beyond sleep: cardiovascular risk, metabolic regulation, cognitive function, and immune timing are all circadian-controlled.

How Does Circadian Disruption Fragment Sleep and Contribute to 3AM Wakeups and Light Shallow Sleep?

Circadian disruption fragments sleep through multiple independent pathways: mistimed wake-promoting orexin neurons that intrude into sleep, peripheral organ clocks that decouple from the brain’s master clock, a thermoregulatory gate that doesn’t open on schedule, a cortisol rhythm that advances too early, and a melatonin timing cue that moves the sleep window away from intended bedtime.

What Is Circadian Disruption and How Does It Affect Sleep Architecture and Disrupt Sleep?

The suprachiasmatic nucleus controls when wake-promoting orexin neurons fire and when REM sleep is permitted. When circadian timing shifts, orexin’s wake drive can extend into the night and REM sleep can appear at the wrong time, fragmenting the normal cycling between sleep stages and producing light, shallow sleep.

The suprachiasmatic nucleus does not directly generate sleep or wakefulness. It relays timing information through the dorsomedial hypothalamus to the orexin (hypocretin) neurons in the lateral hypothalamus — and these orexin neurons are what stabilize the boundary between sleep and wake states.

Orexin is a nonredundant integrator. A 2022 review in Journal of Internal Medicine (Jacobson, Hoyer, de Lecea) described the orexin neuropeptide as a hub that receives circadian, metabolic, and emotional inputs and converts them into a single consolidated wake-promoting output. When orexin-producing neurons are lost in humans, the result is narcolepsy type 1 — characterized by sleep intruding into wakefulness — establishing that orexin is essential for maintaining the stability of waking states. Orexin activity is temporally gated by the circadian clock: it amplifies wakefulness during the active phase and withdraws during the sleep phase.

What happens when the orexin relay weakens? A 2025 study in Neurobiology of Disease (Yuge et al.) tested this in a Rett syndrome mouse model with attenuated orexin receptor expression. These animals slept in short, fragmented bouts with frequent transitions between wakefulness and NREM sleep during their active period — the circadian clock itself was intact, but orexin’s stabilizing output was insufficient to maintain consolidated wake or sleep states. The deficit was selective: the clock was running, but the output couldn’t hold.

Aging may produce a milder version of this same pattern. A 2026 review in Ageing Research Reviews (Alhajaji et al.) described how normal aging is associated with reduced slow-wave and REM sleep, decreased sleep efficiency, increased fragmentation, and dampened circadian amplitude — a phenotype that resembles partial orexin weakening. Dual orexin receptor antagonists show promise for insomnia in older adults, suggesting that the orexin-circadian interface is undercharacterized but relevant in age-related sleep disruption.

What Are Peripheral Clocks, What Is Peripheral Clock Decoupling, and How Does It Contribute to Poor Sleep and Light Shallow Sleep?

Every organ runs its own circadian clock, synchronized by the suprachiasmatic nucleus. When competing inputs — irregular meal timing, erratic schedules, inconsistent light exposure — decouple these peripheral clocks from the master clock, metabolic and hormonal rhythms misalign with sleep-wake timing, producing restless and shallow sleep.

The suprachiasmatic nucleus synchronizes peripheral organ clocks through electrical signaling, endocrine outputs, and metabolic cues (Albrecht, Neuron, 2012). But peripheral clocks also respond to local inputs — particularly feeding and fasting cycles — that can operate independently of light.

This creates a vulnerability. If feeding timing conflicts with the light-dark cycle — as it does with late-night eating or erratic meal schedules — peripheral clocks can decouple from the suprachiasmatic nucleus while the central clock remains intact.

A 2015 study in the FASEB Journal (Cuesta, Cermakian, Boivin) demonstrated this directly in humans. After a simulated night shift protocol, bright light re-entrained the central clock within 3 days. But peripheral clocks in peripheral blood mononuclear cells lagged behind — the central and peripheral clocks were running on different schedules simultaneously. This was the first human demonstration that central-peripheral decoupling occurs with different re-entrainment rates.

A 2024 review in Advances in Experimental Medicine and Biology (Engin) mapped how this works at the molecular level: peripheral clocks in the liver respond to feeding/fasting state, nutrients, and sleep-wake cycles — distinct from the light-entrained suprachiasmatic nucleus. Night-eating specifically decouples peripheral clocks from central timing, while time-restricted eating restores alignment. In multi-oscillator models, this desynchronization is mediated by exosome-based intercellular communication between tissues.

Social jetlag — the gap between biological clock timing and social obligations — is common in industrialized populations and represents a chronic form of this misalignment.

How Does Core Body Temperature Change Throughout the Day and How Does That Affect Sleep Onset and Falling Asleep?

Core body temperature follows a circadian rhythm — highest in late afternoon, declining through the evening, reaching its lowest point during sleep. Sleep onset requires a drop of approximately 1.3°C driven by skin vasodilation. When this temperature rhythm shifts or flattens, the body cannot cool into sleep mode on schedule.

Sleep onset is gated by thermoregulation. As evening approaches, the suprachiasmatic nucleus reduces sympathetic tone to peripheral vasculature, allowing blood to flow to the hands and feet. Heat dissipates through the skin. Core body temperature drops — by approximately 1-1.5°C from its afternoon peak (Harding et al., Frontiers in Neuroscience, 2019). Warm-sensing neurons in the preoptic and anterior hypothalamus activate during sleep onset and NREM sleep, driving the autonomic changes that lower core temperature (Szymusiak, Handbook of Clinical Neurology, 2018).

A meta-analysis in Neuropsychopharmacology (Kräuchi and Wirz-Justice, 2001) found that the distal-proximal skin temperature gradient — the difference between hand/foot temperature and trunk temperature, reflecting heat loss from the core — was the single best predictor of how quickly someone falls asleep. It outperformed core body temperature itself, heart rate, melatonin onset, and subjective sleepiness.

When the circadian temperature rhythm is misaligned, this gate doesn’t open on time. A 2021 study in Sleep Medicine (Kimura et al.) demonstrated this in 28 school-age children with circadian rhythm sleep-wake disorder using fixed lights-out at 21:00, morning phototherapy, and light exercise. Sleep onset shifted from 23:53 to 21:17 (p < 0.001). Post-treatment mean core body temperature was lower (p = 0.011) and minimum sleep temperature was lower (p < 0.001) — as circadian phase realigned, the temperature rhythm followed, and the thermoregulatory gate opened earlier.

Hormonal changes can compound the temperature effect. A 2024 review in Menopause (Maki, Panay, Simon) described how hypothalamic KNDy neurons (kisspeptin/neurokinin B/dynorphin) integrate the gonadotropin-releasing hormone pathway with body temperature control and circadian sleep-wake regulation — linking hormone-driven thermoregulatory disruption to sleep onset failures.

How Does the Circadian Rhythm Affect Cortisol Timing and How Does Disrupted Cortisol Timing Disrupt Sleep and Contribute to 3AM Wakeups?

Cortisol follows a circadian rhythm — lowest in early sleep, rising gradually toward morning. When this rhythm phase-advances with aging or circadian disruption, the cortisol rise begins hours before intended wake time, producing the characteristic 2-3am wakeup. This is a clock-timing problem — the cortisol rhythm has moved, regardless of whether total cortisol levels are elevated.

The hypothalamic-pituitary-adrenal axis follows a circadian pattern. Cortisol drops after sleep onset, reaches its lowest point in the first few hours of the night, then begins a gradual rise that peaks shortly after waking — the cortisol awakening response. Deep sleep actively suppresses cortisol output, and the morning rise helps transition the brain back to wakefulness.

A study in Hormone Research (Van Cauter et al., 1998) showed that in older adults, the 24-hour cortisol rhythm is dampened in amplitude and phase-advanced — the morning cortisol rise begins earlier. The cortisol nadir is higher. Sleep loss in young subjects produced the same endocrine disturbances as aging, suggesting that declining sleep quality may itself drive cortisol rhythm changes.

The functional consequence is measurable. A review in American Journal of Geriatric Psychiatry (Buckley and Schatzberg, 2005) linked elevated nocturnal cortisol and a blunted cortisol nadir to reduced slow-wave sleep and impaired declarative memory consolidation.

Because cortisol functions as a wake-promoting hormone, a phase-advanced cortisol rise can produce early-morning waking — the 2-3am wakeup where the mind is alert and active, not groggy or confused.

A 2023 review in Neuroscience and Biobehavioral Reviews (de Leeuw et al.) documented that the circadian clock regulates cortisol as part of a broad set of bodily functions, and aging, shift work, and jet lag each disrupt the circadian cortisol pattern.

This mechanism is distinct from the stress-driven cortisol elevation covered in the autonomic cause page. The autonomic page addresses chronic HPA axis overactivation — cortisol levels that are elevated because of sustained stress. This section addresses the clock advancing cortisol’s timing — the rise begins earlier, regardless of whether total cortisol is elevated.

How Does the Circadian Rhythm Affect Melatonin Release and How Does Disrupted Melatonin Timing Disrupt Sleep and Contribute to Light Shallow Sleep?

Melatonin is a timing cue that tells the body night has arrived. The suprachiasmatic nucleus controls pineal melatonin secretion, and the onset of melatonin under dim light conditions (dim-light melatonin onset, or DLMO) marks when the body’s sleep window opens. When DLMO moves — from evening light exposure, aging, or pineal calcification — the sleep window moves away from intended bedtime, and sleep that occurs outside this window tends to be lighter and more fragmented.

Melatonin acts through MT1 and MT2 receptors in the suprachiasmatic nucleus and functions as a circadian coordinator — telling the body when night has arrived — rather than as a sleep-inducing agent (Comai et al., Journal of Pineal Research, 2024).

The dim-light melatonin onset is the most accurate marker of circadian phase position. A review in Progress in Neuro-Psychopharmacology and Biological Psychiatry (Pandi-Perumal et al., 2007) established DLMO as the gold-standard tool for evaluating sleep onset problems, determining whether an individual is entrained to a 24-hour light/dark cycle, and identifying optimal timing for chronotherapy.

DLMO responds predictably to light exposure. Morning light advances circadian phase; evening light delays it. Exogenous melatonin has a phase response curve approximately 12 hours out of phase with the light curve — meaning melatonin administered in the afternoon advances the clock, while melatonin in the morning delays it (Lewy et al., Ciba Foundation Symposium, 1995).

When DLMO shifts, the consequences are measurable. A 2024 study in Sleep (Chakraborty et al.) found that myopic children had DLMO delayed by 1 hour and 8 minutes compared to non-myopic peers (9:07 PM vs. 7:59 PM, p = 0.002) and approximately 42% lower nocturnal melatonin output (p = 0.001). These children also had delayed sleep onset, reduced sleep quality, and more evening-type chronotype preference.

The existing TLV melatonin articles cover supplementation in detail. This section is about the clock’s melatonin timing cue — what happens when the internal signal moves, not what happens when you take melatonin as a supplement.

What Triggers or Worsens Circadian Sleep Disruption?

Several factors can disrupt circadian timing — some behavioral, others biological.

Gut microbiome changes weaken peripheral clock entrainment, aging dampens the suprachiasmatic nucleus, medications can suppress melatonin secretion, inflammation and hypoxia disrupt peripheral clocks directly, and insulin resistance feeds back into clock gene disruption. Artificial light, irregular schedules, caffeine, and exercise timing add behavioral load on top of these biological vulnerabilities.

1. How Does the Gut Microbiome Influence Circadian Timing?

Gut bacteria produce short-chain fatty acids — particularly butyrate — that entrain peripheral clocks by modifying gene expression of core clock components like PER2. When the microbiome is disrupted, this entrainment weakens, and peripheral clocks in the gut can decouple from the suprachiasmatic nucleus.

A 2025 review in Frontiers in Microbiology mapped this pathway in experimental models: butyrate produced by gut bacteria inhibits histone deacetylases (HDACs), leading to chromatin remodeling and enhanced expression of the clock gene PER2. Short-chain fatty acids can also reach the central nervous system by crossing the blood-brain barrier or by activating vagus nerve pathways, potentially modulating central circadian rhythms.

The relationship is bidirectional.

Circadian disruption alters the gut microbiome, and an altered microbiome weakens circadian entrainment — creating a reinforcing loop. Time-restricted feeding has been shown to restore microbial rhythmicity in models of circadian disruption, but the improvement requires a functional intestinal circadian clock to translate into anti-inflammatory outcomes.

2. How Does Aging Change Circadian Function?

With aging, the suprachiasmatic nucleus loses neurons and its output weakens, melatonin production declines due to pineal calcification, circadian amplitude dampens, and the phase of multiple rhythms — including cortisol and body temperature — advances earlier. These changes are gradual but cumulative.

Van Cauter et al. (1998) documented the endocrine consequences: the cortisol rhythm flattens, the cortisol nadir rises, and the morning cortisol response phase-advances. A 2026 review in Ageing Research Reviews (Alhajaji et al.) described how these changes produce reduced slow-wave sleep, decreased sleep efficiency, and increased fragmentation — with insomnia prevalence reaching 20-40% in older populations.

A 2026 review in Frontiers in Neuroscience linked age-related melatonin decline to pineal calcification and reduced circadian amplitude, noting that melatonin’s antioxidant and mitochondrial-protective functions decline in parallel.

The degree of circadian weakening varies between individuals. Consistent light exposure, regular meal timing, and physical activity can help maintain circadian amplitude with age.

3. Can Medications Disrupt Circadian Timing?

Some commonly prescribed medications affect circadian function. Beta blockers suppress melatonin secretion by blocking the sympathetic pathway to the pineal gland. NSAIDs can alter glucocorticoid rhythms. The timing of medication administration can influence its interaction with the circadian clock.

Beta-adrenergic blockers reduce nocturnal melatonin secretion by interfering with the sympathetic pathway from the suprachiasmatic nucleus to the pineal gland — the same pathway that normally triggers melatonin production at night. For adults taking beta blockers for blood pressure or heart rate management, this can mean a delayed or blunted melatonin onset independent of any behavioral factor.

The timing of medication administration matters more broadly. Research in chronopharmacology has found that circadian rhythms can influence how effectively a drug works, depending on which circadian-regulated pathways it interacts with and when during the 24-hour cycle it is administered.

This is explanatory, not prescriptive. If a medication is serving a necessary function, that conversation belongs with your physician. The point is that medication effects on circadian timing are a recognized mechanism.

4. Can Inflammation Disrupt Peripheral Clocks Directly?

Inflammation suppresses clock gene expression in peripheral tissues — independently of any lifestyle or behavioral factor. In people with inflammatory bowel disease, intestinal biopsies show reduced circadian clock gene expression. Inflammatory NF-κB activity directly interferes with the BMAL1/CLOCK transcription loop, and the relationship is bidirectional: disrupted peripheral clocks amplify inflammatory output.

A 2024 study in the International Journal of Molecular Sciences showed that lipopolysaccharide-induced inflammation perturbed clock gene oscillations in the hypothalamus, hippocampus, and liver — and triggered neuroinflammation that altered the diurnal behavior of microglia. The clock disruption was a consequence of inflammation, not of any behavioral or lifestyle change.

A 2025 review in Clinical Science documented how inflammatory bowel disease dampens circadian rhythms in the colon, possibly by suppressing BMAL1 expression. This can create a reinforcing cycle: circadian disruption hinders the development of an adequate immune response, and inadequate immune regulation amplifies inflammation — which further suppresses clock gene expression.

The molecular interface is direct. A 2025 review in Frontiers in Immunology described how clock proteins interact directly with components of the NF-κB pathway — meaning inflammation and circadian regulation are mechanistically interlinked, not just correlated.

5. Does Low Oxygen Disrupt Peripheral Clocks?

Hypoxia — including the intermittent oxygen drops that occur in obstructive sleep apnea — can phase-shift peripheral clocks in a tissue-specific way, causing organs to fall out of sync with each other and with the suprachiasmatic nucleus.

A study in PNAS (Adamovich et al.) showed that in vivo hypoxia phase-shifted peripheral clocks in a mouse model, but not uniformly — different tissues responded differently. Feeding restored the liver clock’s original phase, but had no effect on the lung and kidney clocks, which retained their hypoxia-induced phase shift. This means different peripheral clocks respond to different zeitgebers, and hypoxia can create intertissue desynchrony — organs literally running on different schedules.

For individuals with obstructive sleep apnea, this has direct relevance. Repeated oxygen desaturation events throughout the night create ongoing peripheral clock misalignment independent of any behavioral factor. A 2024 review in Circulation Research described the circadian clock-hypoxia interaction as a contributor to cardiovascular risk in sleep-disordered breathing.

6. Can Insulin Resistance Affect Circadian Timing?

Peripheral clocks in the liver regulate the timing of glucose production and insulin sensitivity. When insulin signaling is impaired, it feeds back to disrupt hepatic clock gene oscillations, and dysregulated hepatic metabolite release can then interfere with clocks in adipose tissue and skeletal muscle — creating a cascade of peripheral desynchronization.

A 2022 review in International Journal of Environmental Research and Public Health (Catalano et al.) described the feedback loop: peripheral clock desynchronization impairs insulin sensitivity, and impaired insulin signaling disrupts hepatic clock gene oscillations — creating a self-reinforcing cycle between metabolic and circadian disruption.

A 2024 review in the Journal of Pineal Research (Speksnijder et al.) examined how the suprachiasmatic nucleus controls glucose homeostasis through neural projections, glucocorticoids, melatonin, and the autonomic nervous system. When circadian desynchrony disrupts these coordinated outputs, glucose regulation loses its normal 24-hour pattern.

This is a metabolic-circadian feedback loop. Type 2 diabetes, metabolic syndrome, and chronic circadian misalignment can each initiate the cycle.

7. How Does Artificial Light at Night Affect the Circadian Clock?

Intrinsically photosensitive retinal ganglion cells detect light via the photopigment melanopsin and signal directly to the suprachiasmatic nucleus. Evening artificial light — particularly short-wavelength light from screens — suppresses melatonin and delays circadian phase in a dose-dependent manner.

A 2023 study in Communications Biology found that high melanopic light in the evening caused dose-dependent increases in sleep latency and reductions in melatonin concentration, while low melanopic light shortened time to fall asleep. A study in Chronobiology in Medicine (2024) reported that 2 hours of evening light exposure produced an average 1.1-hour circadian phase delay. A 2025 preprint (medRxiv, not yet peer-reviewed) found that melanopic equivalent daylight illuminance was a more sensitive predictor of sleep quality and structure than traditional photopic illuminance measures.

8. Does an Irregular Schedule Disrupt Circadian Timing?

Social jetlag — the gap between biological clock timing and social obligations — is common in industrialized populations. Irregular sleep-wake schedules prevent the suprachiasmatic nucleus from maintaining stable phase alignment, and the resulting circadian misalignment is associated with metabolic, cardiovascular, and cognitive consequences.

A 2025 study in Sleep (Hasler et al.) measured circadian phase shifts between school nights and weekends in high-school students, demonstrating that even routine weekly schedule variation produces measurable DLMO shifts. A 2025 review in Circulation Research linked sleep irregularity to cardiometabolic risk, framing it as a component of multidimensional sleep health.

9. How Does Caffeine Affect the Circadian Clock?

Caffeine delays the circadian melatonin rhythm by approximately 40 minutes when consumed 3 hours before bedtime — nearly half the phase-shifting effect of bright evening light. It acts through adenosine receptors, modulating the cAMP signaling that is a core component of the cellular circadian clock.

A double-blind, placebo-controlled study in Science Translational Medicine (Burke et al., 2015) showed that a dose equivalent to a double espresso consumed 3 hours before bedtime delayed the circadian melatonin rhythm by approximately 40 minutes. In cell cultures, continuous caffeine exposure lengthened the period of the cellular circadian clock through adenosine receptor and cAMP pathways — suggesting caffeine affects circadian timing at the molecular level, not just through adenosine-mediated sleep pressure.

10. Can Exercise Timing Shift Circadian Rhythms?

Exercise is a non-photic zeitgeber that can entrain peripheral clocks through heat, glucocorticoid release, and mechanical loading. Evening exercise raises nocturnal body temperature and can reduce REM sleep, while morning exercise reinforces the central clock and phase-advances circadian timing.

Research on exercise timing and circadian rhythms has found that evening exercise can raise nocturnal body temperature and reduce REM sleep duration, while morning exercise tends to reinforce the central clock. A study on circadian phase response to exercise (Thomas et al., Journal of Physiology, 2020) found that morning exercise induced phase advance of approximately 0.6 hours.

Exercise-induced factors — heat, glucocorticoid release, and mechanical loading — can entrain peripheral clocks in tissues including skeletal muscle and connective tissue, making exercise timing a relevant non-photic zeitgeber for peripheral circadian alignment.

How Do You Know If Circadian Disruption Is Affecting Your Sleep?

Several patterns suggest circadian involvement: difficulty falling asleep at the intended time despite being tired, waking much earlier than planned, feeling alert at night and sluggish in the morning, or a noticeable shift in sleep timing between workdays and weekends.

Circadian phase can be measured through melatonin onset, cortisol rhythm analysis, skin temperature tracking, and actigraphy.

What Does Circadian Sleep Disruption Feel Like?

The hallmark is a mismatch between when you want to sleep and when your body will permit it.

You may lie awake at your chosen bedtime with no drowsiness, or wake hours before your alarm fully alert. A large weekend shift — sleeping later on free days than workdays — is a common indicator of underlying circadian misalignment.

• Can’t fall asleep at intended time despite being tired. The body is fatigued but the circadian clock has not opened the sleep window — melatonin onset has not occurred, core body temperature has not dropped, and the orexin wake-promoting drive is still active.

• Waking 2-3 hours before your alarm, fully alert. This is consistent with a phase-advanced cortisol rhythm — the circadian cortisol rise has arrived earlier than intended, triggering an alert wakeup before the desired wake time.

• Energy peak at the wrong time of day. Alert at midnight, sluggish at 8am — or the reverse. The circadian rhythm is running, but on a different schedule from the one your obligations require.

• Large weekend shift. Sleeping 1-2 or more hours later on free days compared to workdays suggests the biological clock is misaligned with the social schedule — the definition of social jetlag.

• Feeling jet-lagged without having traveled. The subjective experience of internal desynchronization — when peripheral clocks, temperature rhythm, cortisol rhythm, and melatonin timing are not aligned with each other or with your schedule.

What Can Be Measured?

Dim-light melatonin onset (DLMO) is the most accurate marker of circadian phase (Pandi-Perumal et al., 2007).

Multi-timepoint saliva sampling — collecting samples at 4 or more time points across the day — can reveal both melatonin onset timing and cortisol rhythm shape, showing whether the circadian rise is phase-advanced or the amplitude is flattened.

• Melatonin rhythm via saliva sampling. Saliva samples collected at multiple timepoints under dim light conditions can identify when melatonin begins to rise — the DLMO — and how it compares to your intended sleep time. A gap between DLMO and bedtime indicates phase misalignment.

• Cortisol rhythm via saliva sampling. Salivary cortisol collected at multiple timepoints — at wake, 30 minutes post-wake, afternoon, and bedtime — reveals the shape of the 24-hour cortisol curve: whether it is flattened, whether the cortisol awakening response is blunted, and whether bedtime cortisol remains elevated or has phase-advanced.

• Skin temperature rhythm. Wearables that track overnight temperature trends can capture the circadian temperature rhythm. The amplitude of this rhythm correlates with sleep quality (Tai et al., JCSM, 2023).

• Actigraphy. Rest-activity pattern regularity over days to weeks captures circadian stability at the behavioral level. Irregular patterns suggest circadian misalignment even when individual nights look normal.

Can Multiple Causes Contribute at Once?

Most people with disrupted sleep have more than one cause contributing. Circadian disruption may coexist with autonomic, metabolic, inflammatory, or hormonal factors. Identifying all contributing causes gives a more complete picture than addressing any single factor.

Find out which causes might be driving your 3am wakeups with the 3AM Decoder →

3AM Decoder

Frequently Asked Questions

• Is Circadian Disruption the Same as Insomnia?

• Does Aging Always Weaken Circadian Rhythms?

• Can a Disrupted Circadian Rhythm Be Reset?

• Is Melatonin Supplementation the Answer to Circadian Sleep Problems?

Is Circadian Disruption the Same as Insomnia?

Insomnia is a description of difficulty sleeping. Circadian disruption is a mechanism — the internal clock is misaligned with the intended sleep schedule. A person with a delayed circadian phase may sleep well if allowed to follow their biological timing, but appear insomniac when forced to sleep on a conventional schedule.

The distinction matters because the solutions differ.

Read more

You already know sleep is more than just feeling rested.

How you sleep is tied to memory, mood, blood pressure, blood sugar, and whether you can show up for the people and activities that matter to you. For years, though, the tools we’ve had to measure sleep and long-term health risk have been …

Read more

The autonomic nervous system controls heart rate, breathing, digestion, and the transition between wakefulness and sleep. When this regulation loses its balance — through weakened parasympathetic braking, reduced inhibitory activity in the brain, or an overactive stress response — the body stays activated when it should be winding down.

Your autonomic nervous system runs in the background. It manages the functions you don’t consciously control — your heart rate, your breathing rhythm, your stress response, and the physiological transition into sleep.

It has two branches.

• The sympathetic branch drives arousal: it raises heart rate, sharpens alertness, and mobilizes energy.

• The parasympathetic branch drives recovery: it slows heart rate, deepens breathing, and supports the transition into sleep.

Healthy sleep depends on the parasympathetic branch taking over as the night begins. Heart rate drops. Breathing slows. Core body temperature falls. The brain moves from high-frequency waking activity into the slower rhythms of deep sleep.

When that handoff doesn’t happen cleanly — when sympathetic tone remains elevated or parasympathetic activation is insufficient — sleep fragments. You may fall asleep but wake too early. You may lie awake with a racing heart despite being exhausted. The body is stuck between two competing states: one trying to sleep, the other still in sympathetic activation — elevated heart rate, heightened alertness, increased cortisol output.

Several mechanisms contribute to autonomic sleep disruption: weakened vagal tone, reduced GABAergic inhibition, and an overactive stress-hormone axis.

Here are 3 common examples:

Subscribe now

How Does Autonomic Dysregulation Disrupt Sleep?

Several mechanisms account for how autonomic dysregulation fragments sleep: reduced vagal tone leaves the body unable to downshift at sleep onset, low GABA leaves the brain unable to suppress its own waking activity, and an overactive HPA axis drives cortisol surges that trigger early-morning waking.

How Does Vagal Tone Affect Sleep?

Vagal tone reflects how strongly the parasympathetic nervous system can slow heart rate and move the body into rest. When vagal tone is low, the transition into sleep is incomplete — heart rate stays elevated, arousal persists, and sleep becomes fragmented.

The vagus nerve is the main conduit of parasympathetic control. It runs from the brainstem to the heart, lungs, and gut, and its activity — measured indirectly through heart rate variability — reflects how effectively the body can transition from alertness to rest.

During healthy sleep, vagal activity increases. Heart rate drops. The body enters a measurably different physiological state. A 2024 study in Stress and Health (Joubert et al.) found that individuals who showed minimal increases in high-frequency heart rate variability at sleep onset — consistent with reduced parasympathetic activation at sleep onset — reported worse sleep quality and greater difficulty with stress the following day.

When vagal tone is low, this transition is incomplete. The body enters sleep with sympathetic activity still elevated — meaning heart rate, blood pressure, and arousal-related neural firing remain higher than they should be during rest. A 2020 study using overnight pulse wave analysis (Laharnar et al., PLoS ONE) found that people with insomnia had higher median overnight heart rate of 66-67 bpm throughout the night, compared to 58 bpm in healthy sleepers. The elevated rate wasn’t confined to moments of waking — it was sustained across the entire sleep period.

A 2025 international expert consensus in Nature Reviews Cardiology (Menuet et al.) argued that respiratory-related HRV is primarily vagally mediated and should be interpreted in relation to breathing. Consumer wearables may help track nighttime HRV trends, and can be a useful proxy of vagal function and vagal tone.

Medications can also weaken vagal and cholinergic activity.

Anticholinergic drugs — a class that includes certain antihistamines, bladder medications, and some antidepressants — work against the same cholinergic pathways the vagus nerve uses.

Their effect on sleep is covered in the triggers section below.

What Role Does GABA Play in Sleep Disruption?

GABA (gamma-aminobutyric acid) is the brain’s primary inhibitory neurotransmitter — the chemical cue that calms neural activity for sleep. When GABAergic tone is reduced, the brain cannot suppress its own activation, making it harder to enter and maintain deep sleep stages.

Several major classes of sleep medication — from barbiturates to benzodiazepines to newer non-benzodiazepine hypnotics — act through GABA receptors. That convergence is not coincidental. GABA is a key mechanism through which the brain reduces its own activity to allow sleep.

A 2024 review in Tzu Chi Medical Journal (Varinthra et al.) mapped how GABAergic impairment directly produces insomnia through multiple receptor subtypes. A companion review in Heliyon (Zhu et al., 2024) identified five independent GABA-related pathways that can contribute to sleep disruption: GABA-A receptor modulation, GABA-B receptor modulation, neuroinflammation, oxidative damage, and circadian melatonin regulation.

In a study published in Sleep (Winkelman et al., 2008), people with primary insomnia had approximately 30% lower whole-brain GABA levels than healthy sleepers, measured using magnetic resonance spectroscopy. The lower the GABA, the more time spent awake after sleep onset.

GABAergic tone is not fixed.

It is vulnerable to multiple disruptors — neuroinflammation, gut microbiome changes, and hormonal changes among them. A 2025 study in Frontiers in Bioscience (Jiang et al.) reported that a GABA-producing bacterial strain altered sleep-related behavior through a microbiota-gut-brain pathway and supports a possible gut–GABA–sleep link. A 2023 study in Nature (Sun et al.) resolved native GABA-A receptor structures and found that allopregnanolone — a neurosteroid derived from progesterone — was bound to the receptor even without external administration, supporting an endogenous hormonal role in maintaining GABAergic function.

When GABA is low, the brain cannot calm itself. Neural circuits that should be suppressed during sleep remain active, producing the experience of lying in bed with a mind that won’t stop running.

Subscribe now

How Do Cortisol and Adrenaline Wake You Up?

Cortisol and adrenaline are the output of the HPA (hypothalamic-pituitary-adrenal) axis — the body’s central stress response. In a normal rhythm, cortisol reaches its lowest point in early sleep and rises gradually toward morning. When that rhythm advances earlier or stays elevated, cortisol can surge hours before your alarm — producing the characteristic 2-3am wakeup with a racing mind.

The HPA axis follows a 24-hour pattern.

Cortisol drops after sleep onset, reaches its nadir in the first few hours of the night, then begins a gradual rise that peaks shortly after waking. This cortisol awakening response is tightly coordinated with sleep architecture — deep sleep actively suppresses HPA output, and the rise toward morning helps the brain transition back to wakefulness.

When cortisol stays elevated or the rhythm flattens, the result is measurable: more nighttime awakenings, less deep sleep, and the characteristic early-morning waking that people describe as “my brain turns on at 3am.”

A 2022 meta-analysis in Sleep Medicine Reviews (Dressle et al.) pooled data from 20 case-control studies involving over 800 participants and found that people with chronic insomnia had moderately elevated cortisol levels compared to healthy sleepers (standardized mean difference 0.50). When restricted to blood-sample studies, the effect was larger (0.67). The elevation was not confined to the morning — it reflected a 24-hour pattern of HPA overactivation.

Cortisol doesn’t just follow a single 24-hour curve — it also pulses in shorter bursts every 60-120 minutes throughout the day and night.

A 2018 review in Sleep Medicine Reviews (Vargas et al.) proposed that these ultradian cortisol pulses can contribute to nocturnal awakenings when they become amplified or mistimed. Normally these pulses are suppressed during deep sleep. When deep sleep is lost, the suppression lifts and cortisol surges become more likely during the vulnerable early-morning hours.

A 2023 study in The Journal of Clinical Endocrinology and Metabolism (Cohn et al.) demonstrated this relationship experimentally: sleep fragmentation increased bedtime cortisol by 27% and decreased the cortisol awakening response by 57%. The more fragmented the sleep, the higher the nighttime cortisol and the flatter the morning response. This creates a self-reinforcing loop — elevated cortisol fragments sleep, and fragmented sleep elevates cortisol.

Sympathetic arousal, including elevated norepinephrine, compounds the effect.

A 2019 review in Autonomic Neuroscience (Grimaldi et al.) described how sympathetic hyperactivity — persistent autonomic overactivation during sleep — is among the better-supported explanations for why insomnia and cardiovascular risk are linked. The arousal doesn’t only happen at the moment of waking. A 2013 study (de Zambotti et al., Clinical Autonomic Research) showed that cardiac sympathetic activation was elevated throughout the entire night in people with insomnia — not just during awakenings, but continuously.

What Triggers or Worsens Autonomic Sleep Disruption?

Autonomic sleep disruption is driven by several converging factors: chronic stress that sustains HPA axis activation, neuroinflammation and gut microbiome changes that weaken GABAergic tone, and medications that interfere with parasympathetic function. Neuroinflammation can disrupt the gut microbiome, gut dysbiosis can amplify inflammation, and both can accelerate hormonal decline — creating overlapping pressure on the same inhibitory circuits.

How Does Chronic Stress Affect Autonomic Sleep Regulation?

Chronic stress keeps the HPA axis in a state of sustained activation, elevating cortisol and suppressing the parasympathetic activation that sleep requires. This creates a self-reinforcing cycle: stress disrupts sleep, and disrupted sleep amplifies the stress response.

The HPA axis is designed for acute activation — a short burst of cortisol and adrenaline in response to a specific demand, followed by a return to baseline. Under chronic stress, the return doesn’t fully happen. Baseline cortisol rises. The 24-hour rhythm flattens.

The Dressle 2022 meta-analysis found this pattern across 20 studies: people with insomnia showed consistent cortisol elevation, supporting the hyperarousal model — the idea that insomnia is a state of multi-level overactivation, not just poor sleep habits.

The relationship between cortisol and sleep is bidirectional. Elevated cortisol fragments sleep. Fragmented sleep, in turn, amplifies cortisol output. The Cohn 2023 experimental data showed a 27% cortisol increase from sleep fragmentation alone, independent of any psychological stressor. For example, a person whose sleep fragmented under sustained work stress can still have elevated nighttime cortisol after the stressor resolves — because the cortisol-sleep loop, once established, can persist for some time (Vargas et al., 2018).

Aging can compound this pattern — cortisol rhythms tend to flatten and phase-advance with age, meaning the early-morning cortisol rise begins earlier. But age is one input among many. Chronic work stress, sustained caregiving demands, or prolonged physiological load can produce the same flattening at any adult stage.

What Disrupts GABAergic Tone?

GABAergic tone — the brain’s capacity to inhibit its own activity for sleep — is vulnerable to neuroinflammation, gut microbiome disruption, and hormonal changes. These factors can reduce GABA availability or impair GABA receptor function, each through a different pathway.

Neuroinflammation. When inflammatory activity is elevated in the brain, it can impair the inhibitory circuits that depend on GABA. Zhu et al. (2024) identified neuroinflammation as one of five independent pathways through which GABAergic impairment produces insomnia. A 2024 study in Nutrients (Lee et al.) showed that stress-induced neuroinflammation — measured by TNF-alpha-positive cells in both the prefrontal cortex and colon — was accompanied by downregulation of GABA, GABA-A receptors, and serotonin. Reducing the inflammation restored GABAergic activity and sleep.

Gut microbiome disruption. The gut can be a site of microbial GABA production, and gut microbes can influence sleep-related signaling through neural, immune, endocrine, and metabolic pathways. A March 2026 study in Biomedicine & Pharmacotherapy (Tung et al.) demonstrated that GABA-producing postbiotics from Levilactobacillus brevis reversed the effects of chronic sleep deprivation in an experimental model — restoring intestinal barrier integrity, reducing serum inflammatory markers, and suppressing neuroinflammatory gene expression in the brain. The implication is that gut dysbiosis may alter sleep-related signaling.

Hormonal changes. Progesterone converts into allopregnanolone, a neurosteroid that potentiates GABA-A receptor function. The Sun et al. (2023) cryo-EM study in Nature found allopregnanolone bound to native GABA-A receptors even without external administration — meaning this is not a pharmacological effect but an endogenous regulatory mechanism. When progesterone declines — whether through hormonal transitions, chronic stress, or other factors — allopregnanolone levels can also decline, which may reduce GABA-A receptor modulation.

These three pathways — inflammation, gut microbiome, and hormonal changes — often coexist and compound each other.

Can Medications Disrupt Autonomic Sleep Regulation?

Anticholinergic medications — a class that includes certain antihistamines, bladder medications, and some antidepressants — work against the same cholinergic pathways the parasympathetic branch uses to maintain sleep. The effect can be cumulative across multiple medications.

Anticholinergic drugs block acetylcholine receptors. Acetylcholine is one of the key neurotransmitters the vagus nerve uses to exert parasympathetic control, and it plays a direct role in REM sleep maintenance.

The impact scales with dose and the number of anticholinergic medications taken concurrently — a concept called anticholinergic burden. For adults taking multiple medications — common in the 40+ age range — the cumulative effect on sleep can be meaningful even when individual drug doses are low.

This is explanatory, not prescriptive. If a medication is serving a necessary function, that conversation belongs with your prescribing physician. The point here is that anticholinergic effects on sleep are a recognized mechanism, and awareness of it can inform that conversation.

Subscribe now

How Do You Know If Autonomic Dysregulation Is Disrupting Your Sleep?

The hallmark of autonomic sleep disruption is waking up alert rather than groggy, often with a racing heart or the feeling of being “wired but tired.”

Heart rate variability during sleep, cortisol patterns, and sleep architecture data can potentially help distinguish autonomic causes from other sleep disruption patterns.

What Does Autonomic Sleep Disruption Feel Like?

Several patterns tend to stand out:

• Waking alert, not groggy. If you wake at 2 or 3am and your mind is active right away — not confused or disoriented — that’s more consistent with a hyperarousal pattern than with a nonspecific awakening.

• Racing heart at rest. Elevated heart rate when you’re lying still, especially at sleep onset or during nighttime awakenings, reflects sympathetic activation that hasn’t subsided.

• “Wired but tired.” Exhaustion paired with an inability to calm down. The body wants sleep; the autonomic state won’t permit it. This is what simultaneous sympathetic activation and parasympathetic insufficiency feels like.

• Difficulty winding down before sleep. If the transition from activity to rest takes an unusually long time — if lying down doesn’t feel like the body is winding down — that may reflect low vagal tone and insufficient parasympathetic engagement.

What Can Be Measured?

A 2023 study in the Journal of Clinical Sleep Medicine (McCall et al.) found that daytime autonomic measurements — including pupillary light reflex speed and heart rate variability — could distinguish between different insomnia severity levels. Autonomic dysregulation was measurable during waking hours, between 3 and 5pm, not only at night.

Several markers are relevant:

• Heart rate variability during sleep. Lower high-frequency or respiratory-related HRV during sleep can reflect reduced vagally mediated cardiac modulation. Some consumer wearables can track HRV trends, but device methods and accuracy vary.

• Cortisol patterns. The Dressle 2022 meta-analysis found cortisol to be a useful biomarker distinguishing insomnia from healthy sleep. Hair cortisol provides a longer-term window (weeks to months) of HPA axis activity.

• Sleep architecture. Reduced deep sleep and increased light-sleep fragmentation can be consistent with autonomic interference with normal sleep staging.

Can Multiple Causes Contribute at Once?

People with disrupted sleep often have more than one cause contributing. Autonomic dysregulation may coexist with metabolic, inflammatory, hormonal, or circadian factors.

Addressing one cause can improve sleep even when others are present — but identifying all the contributing factors gives you a more complete picture.

Find out which causes are driving your 3am wakeups with the 3AM Decoder →

3AM Decoder

Frequently Asked Questions I Get From Clients

• Does Autonomic Dysregulation Mean Something Is Wrong With My Nervous System?

• Can Heart Rate Variability From a Wearable Tell Me If I Have Autonomic Sleep Disruption?

• Is Cortisol Testing Useful for Identifying Autonomic Sleep Disruption?

• Can Autonomic Sleep Disruption Improve Without Medication?

Does Autonomic Dysregulation Mean Something Is Wrong With My Nervous System?

Read more

It’s a reasonable question. You did fall asleep faster. The calming effect was there. The question is what happens in the hours that follow, while the body processes what you drank.

Here are 4 ways alcohol affects the second half of your sleep,…

Read more

Two areas of longevity science I keep coming back to — both in my own work and in my own health. I think the gut-sleep connection is one of the more underappreciated intersections in health, and it’s something I’ve wanted to explore in a focused conversation for a while.

Today I get to do that — through a written Q&A with Scott C. Ander…

Read more

She’s diligent, kind, and always booked solid—20‑minute appointments stacked one after another, often with patients waiting because she never rushes anyone.

Watching her juggle those demands shows that the challenge isn’t a lack of care from doctors, but the structure they’re working inside.

The healthcare system was built to protect populations from disease, not to guide individuals toward longevity.

In that role, it does what it’s designed to do.

But if your goal is to stay ahead of aging, the very design that keeps the system functional also creates limitations.

Subscribe now

This is the lens we need to adopt.

Respect the system for what it does well, but recognize that longevity requires a different way of reading the same information—for example, the bloodwork you already get in routine care.

Section 2: Population Logic — Why Normal Ranges Weren’t Built for You and Me

If every subtle shift in lab results were flagged, the healthcare system would seize up.

Current thresholds are set primarily to identify clear pathology—conditions like diabetes, kidney dysfunction, advanced liver damage, anemia, or active infection—rather than to detect early risk.

The priority is ensuring that disease is recognized and managed efficiently within available resources.

Right now, a sub-fraction of routine laboratory results are indicated for follow‑up.

If ranges were tightened to reflect where research shows risk begins, the proportion of abnormal results would rise dramatically. That could mean a majority of patients requiring some form of follow‑up.

Each flagged result triggers a cascade of work:

• physician review,

• patient communication & appointment scheduling,

• consideration of further testing,

• documentation & insurance authorization.

Multiply this across millions of test results per day, and the burden quickly surpasses available time and resources.

This does not reflect indifference by physicians.

Rather, it highlights a structural reality: if high‑normal results were indicated as risks, the resulting workload would overwhelm the system.

For individuals pursuing longevity, however, this reality means that early declines often remain outside the scope of what the conventional healthcare system will detect or can act upon.

Section 3: The Protocol Gap — Why Borderline Normal Has No Playbook

Even when physicians recognize concerning patterns in borderline-normal values, the conventional healthcare system provides no structured guidance for interpretation or response.

Guidelines and reimbursement structures are built on binary logic: abnormal values trigger defined diagnostic pathways, while results within the reference range requires no action.

This framework leaves little to no space for the nuanced middle ground where the most actionable health decline occurs.

Consider a physician reviewing results where fasting insulin measures 12 μIU/mL—elevated from the patient’s historical baseline of 6 μIU/mL, but still within the laboratory’s reference range of 2–25 μIU/mL.

The physician probably recognizes this pattern as possible early insulin resistance. Yet clinical guidelines provide no standardized protocol for this scenario.

• Insurance systems don’t cover follow-up testing for “normal” results.

• There is no established timeframe for reassessment, no clear intervention threshold, and no reimbursement pathway for preventive management.

The likely outcome is clinical limbo: documentation and deferral until values cross the abnormal threshold.

When high-normal values consistently receive no clinical attention, they become psychologically invisible in practice. The cognitive pattern of “normal = no action” becomes ingrained. Over time, this absence of pathways creates a form of institutional “blindness,” where gradual biological shifts remain unaddressed.

The reinforcement runs deeper than individual practice:

• Medical education emphasizes pathology recognition over trajectory monitoring.

• Board examinations test knowledge of disease states, not prevention protocols.

• Continuing medical education mainly focuses on managing established conditions rather than intercepting early decline into possible disease.

The result is inertia.

From the individual’s perspective, this trade-off functions like implicit rationing.

Section 4: Where System Constraints End and Personal Agency Begins

The limits described above exist because the healthcare system must serve entire populations.

But we as individuals are not bound by those same constraints.

We don’t need to wait for values to cross diagnostic thresholds before paying attention.

By looking at personal baselines, research-informed ranges, and changes that persist over time, it’s possible for us to see meaningful signals long before the system is designed to act.

This perspective doesn’t replace medical care.

It simply emphasizes that longevity requires a different lens: one that interprets “normal” results as part of a trajectory, not a verdict.

So what does this look like in practice?

Section 5: Beyond Standard Labwork Interpretation — Why We Can’t Outsource Early Detection & What We Can Do Instead

As emphasized throughout, conventional medicine excels at diagnosing pathology, but it wasn’t built to guide optimal longevity trajectories.

Take high-sensitivity C-reactive protein (hsCRP) as an example.

On a standard lab report, results may only be flagged when levels are markedly elevated. Yet research shows meaningful cardiovascular and longevity risk emerge below those cutoffs.

Looking at hsCRP through a longevity lens reveals a different picture:

If your hsCRP comes back at 2.0 mg/L, your physician may tell you it’s fine—and within the system’s logic, it is.

But from a longevity perspective, it signals that your inflammatory load is already elevated compared to truly low-risk individuals.

By considering research-based ranges, you can use hsCRP as an early cue to adjust the levers within your control:

• Sleep quality: Even modest reductions in sleep quality or duration can elevate hsCRP.

• Dietary patterns (carbohydrates & fiber): Excess refined carbs raise hsCRP, while fiber and gut-supportive foods help lower it.

• Dietary patterns (nutrients & phytonutrients): Adequate omega-3 intake and polyphenol-rich foods (berries, olive oil, green tea) are associated with lower inflammation.

• Body composition: Abdominal fat is metabolically active and raises baseline inflammation.

• Environmental exposures: Air pollutants, poor indoor air quality, and certain toxins can chronically elevate hsCRP.

  

Small adjustments in these areas can nudge hsCRP down over time, moving you closer to the longevity-optimal range.

But looking at a single marker is only the first layer. Once you start reading hsCRP differently, complexity emerges:

• Personal baselines: A result of 0.8 mg/L may appear fine, but if your historical baseline is 0.2, that’s a fourfold increase—context matters.

• Persistence vs. spikes: Was the elevation a one-off after a recent cold, or has it stayed high for months? The answer changes its significance.

• Multi-marker drift: hsCRP gains more meaning when paired with related markers. For example, rising hsCRP alongside fasting glucose or triglycerides suggests systemic strain rather than a transient blip.

• Marker selection: hsCRP is only one of several inflammation-linked measures. Ferritin, white blood cell count, IL-6, or uric acid can provide complementary signals of immune tone and metabolic stress.

Takeaway: Even a standard marker like hsCRP can become a practical tool when you view it as part of a trajectory instead of a static number.

Acting on small deviations today—through sleep, diet, body composition, and environment—can change your aging trajectory years before the healthcare system could intervene.

The challenge is scaling this perspective across many markers.

How do you weigh shifts in insulin, glucose, and inflammation together? How do you separate lab variation from true decline? And what other markers should you be looking at and acting on before they reach clinical thresholds?

That’s where the Vault SPIRAL System comes in: my framework designed to capture not just one number, but the patterns across time, across markers, relative to your own baseline, and how to take action.

The Vault Before-It’s-Abnormal Lab Intelligence System

—My 6-Part Framework To Detect Early Aging from Routine Labs & Reverse Course (SPIRAL)—$67

Most decline starts inside the normal range. SPIRAL shows you where to act early.

The Prevention Gap Most Adults Face

Everyone understands that prevention is better than treatment.

Yet most people inevitably wait for "abnormal" lab results before taking action on their health.

The challenge isn't knowing that normal ranges aren't optimal—it's knowing how to systematically move from your current normal toward your personal optimal.

SPIRAL bridges that gap.

It transforms routine bloodwork from a static health snapshot into a dynamic tool for early detection and course correction, years before conventional medicine would intervene.

The complete SPIRAL system includes the step-by-step framework plus implementation worksheets, tracking templates, and optimization reference guides for 12 key markers where longevity-optimal ranges differ from standard "normal" ranges.

What You Get With The Vault Before-It's-Abnormal Lab Intelligence System

Module 1. The 6-Part Framework —Early-Detection Framework to Help You Catch Early Health Decline and Reverse Course Without Waiting for a Medical Diagnosis or Adding Complex Bloodwork

12 Critical Markers Analysis: Longevity-optimal ranges for hsCRP, fasting insulin, triglycerides, WBC, and 8 other markers where normal isn’t optimal.

Module 2. The Act-Before-Abnormal Action Guide — The Before-It’s-Abnormal Lab Intelligence System Operating Manual For Acting Early Inside The Normal Range

Personal Biology Manual: Framework for documenting what affects your unique physiology and what reliably restores your baseline.

You can access The Vault Before-It’s-Abnormal Lab Intelligence System Here for just $67:

Get the Before-It's-Abnormal Lab System

You shouldn’t have to wait for abnormal results to prevent health decline. With The Vault Before-It’s-Abnormal Lab Intelligence System, you won’t.

P.S. Vault Insider Exclusives, you can access this complete system as part of your membership here, along with all previous & future optimization frameworks throughout the year.

How To Get Lab Tests:

All SPIRAL markers are standard blood tests that clinicians and national labs can run (relatively inexpensively).

Inside the SPIRAL system, you’ll get a marker list plus access to the Vault SPIRAL Companion Lab Shop, which bundles the recommended markers into ready-to-order panels you can use in most U.S. states.

You can also take the same marker list to your own physician or a national lab service (such as Quest or Labcorp) and run the tests through your usual channels.

Just a reminder that direct self-ordering has state-specific limitations (for example, the Vault Lab Shop is not available for self ordering in NY, NJ, or RI), and different services have different rules, but the portals will automatically show what’s available for your location.

References

• Timbrell NE. The Role and Limitations of the Reference Interval Within Clinical Chemistry and Its Reliability for Disease Detection. Br J Biomed Sci. 2024 Feb 28;81:12339. doi: 10.3389/bjbs.2024.12339. PMID: 38481978; PMCID: PMC10932992.

• Magni, O., Arnaoutis, G. & Panagiotakos, D. The impact of exercise on chronic systemic inflammation: a systematic review and meta–meta-analysis. Sport Sci Health (2025). https://doi.org/10.1007/s11332-025-01445-3

• Docherty, S., Harley, R., McAuley, J.J. et al. The effect of exercise on cytokines: implications for musculoskeletal health: a narrative review. BMC Sports Sci Med Rehabil 14, 5 (2022). https://doi.org/10.1186/s13102-022-00397-2

• Aqeel, M.; Forster, A.; Richards, E.A.; Hennessy, E.; McGowan, B.; Bhadra, A.; Guo, J.; Gelfand, S.; Delp, E.; Eicher-Miller, H.A. The Effect of Timing of Exercise and Eating on Postprandial Response in Adults: A Systematic Review. Nutrients 2020, 12, 221. https://doi.org/10.3390/nu12010221

• van der Spoel E, Roelfsema F, van Heemst D. Within-Person Variation in Serum Thyrotropin Concentrations: Main Sources, Potential Underlying Biological Mechanisms, and Clinical Implications. Front Endocrinol (Lausanne). 2021 Feb 24;12:619568. doi: 10.3389/fendo.2021.619568. PMID: 33716972; PMCID: PMC7945716.

• Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, Mullington JM. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004 Feb 18;43(4):678-83. doi: 10.1016/j.jacc.2003.07.050. PMID: 14975482.

• van Leeuwen WM, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, Härmä M, Porkka-Heiskanen T, Alenius H. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS One. 2009;4(2):e4589. doi: 10.1371/journal.pone.0004589. Epub 2009 Feb 25. PMID: 19240794; PMCID: PMC2643002.

• Chen C, Liu Y, Cao Z, Yin Z, Zhao F, Lv Y, Liu Z, Mao C, Song S, Liu L, Qu Y, Ji S, Duan J, Wang J, Kraus VB, Zeng Y, Shi X. Combined associations of hs-CRP and cognitive function with all-cause mortality among oldest-old adults in Chinese longevity areas: a prospective cohort study. Immun Ageing. 2019 Nov 17;16:30. doi: 10.1186/s12979-019-0170-y. PMID: 31832073; PMCID: PMC6859603.

• Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004 Apr 27;109(16):1955-9. doi: 10.1161/01.CIR.0000125690.80303.A8. Epub 2004 Mar 29. PMID: 15051634.

• Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004 Apr 27;109(16):1955-9. doi: 10.1161/01.CIR.0000125690.80303.A8. Epub 2004 Mar 29. PMID: 15051634.

• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107(3):499-511. doi: 10.1161/01.cir.0000052939.59093.45. PMID: 12551878.

• Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: An Indian perspective. Indian J Med Res. 2015 Sep;142(3):261-8. doi: 10.4103/0971-5916.166582. PMID: 26458341; PMCID: PMC4669860.

• Tohidi M, Ghasemi A, Hadaegh F, Derakhshan A, Chary A, Azizi F. Age- and sex-specific reference values for fasting serum insulin levels and insulin resistance/sensitivity indices in healthy Iranian adults: Tehran Lipid and Glucose Study. Clin Biochem. 2014 Apr;47(6):432-8. doi: 10.1016/j.clinbiochem.2014.02.007. Epub 2014 Feb 14. PMID: 24530467.

• Larsson A, Stridsberg M, Lind L. Reference values for fasting insulin in 75 year old females and males. Clin Biochem. 2013 Aug;46(12):1125-1127. doi: 10.1016/j.clinbiochem.2013.03.024. Epub 2013 Apr 9. PMID: 23578739.

• Hammel MC, Stein R, Kratzsch J, Vogel M, Eckert AJ, Triatin RD, Colombo M, Meigen C, Baber R, Stanik J, Spielau U, Stoltze A, Wirkner K, Tönjes A, Snieder H, Holl RW, Stumvoll M, Blüher M, Kiess W, Körner A. Fasting indices of glucose-insulin-metabolism across life span and prediction of glycemic deterioration in children with obesity from new diagnostic cut-offs. Lancet Reg Health Eur. 2023 May 23;30:100652. doi: 10.1016/j.lanepe.2023.100652. PMID: 37465325; PMCID: PMC10350850.

• Geoffrey C. Kabat, Mimi Y. Kim, JoAnn E. Manson, Lawrence Lessin, Juan Lin, Sylvia Wassertheil-Smoller, Thomas E. Rohan, White Blood Cell Count and Total and Cause-Specific Mortality in the Women's Health Initiative, American Journal of Epidemiology, Volume 186, Issue 1, 1 July 2017, Pages 63–72, https://doi.org/10.1093/aje/kww226

• Ruggiero C, Metter EJ, Cherubini A, Maggio M, Sen R, Najjar SS, Windham GB, Ble A, Senin U, Ferrucci L. White blood cell count and mortality in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2007 May 8;49(18):1841-50. doi: 10.1016/j.jacc.2007.01.076. Epub 2007 Apr 23. PMID: 17481443; PMCID: PMC2646088.

• de Labry LO, Campion EW, Glynn RJ, Vokonas PS. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. J Clin Epidemiol. 1990;43(2):153-7. doi: 10.1016/0895-4356(90)90178-r. PMID: 2303845.

• Furman, D., Campisi, J., Verdin, E. et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 25, 1822–1832 (2019). https://doi.org/10.1038/s41591-019-0675-0

• Welsh C, Welsh P, Mark PB, Celis-Morales CA, Lewsey J, Gray SR, Lyall DM, Iliodromiti S, Gill JMR, Pell J, Jhund PS, Sattar N. Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. Arterioscler Thromb Vasc Biol. 2018 Jun;38(6):1415-1423. doi: 10.1161/ATVBAHA.118.310945. Epub 2018 Apr 26. PMID: 29699973.

• Wang, H., Kim, S.J., Lei, Y. et al. Neutrophil extracellular traps in homeostasis and disease. Sig Transduct Target Ther 9, 235 (2024). https://doi.org/10.1038/s41392-024-01933-x

• Neves PRDS, Tenório TRDS, Lins TA, Muniz MTC, Pithon-Curi TC, Botero JP, Do Prado WL. Acute effects of high- and low-intensity exercise bouts on leukocyte counts. J Exerc Sci Fit. 2015 Jun;13(1):24-28. doi: 10.1016/j.jesf.2014.11.003. Epub 2015 Feb 7. PMID: 29541095; PMCID: PMC5812872.

• Peake JM, Neubauer O, Walsh NP, Simpson RJ. Recovery of the immune system after exercise. J Appl Physiol (1985). 2017 May 1;122(5):1077-1087. doi: 10.1152/japplphysiol.00622.2016. Epub 2016 Dec 1. PMID: 27909225.

Read more

Waking to urinate once or twice overnight sits within the range of normal kidney physiology — kidneys have their own circadian rhythm, and their activity reduces during sleep, but they don’t stop.

The challenge is when waking to urinate becomes a disruption in itself: the peeing happens, and then sleep doesn’t return. That’s a different kind of problem than urination frequency alone.

There are multiple explanations for this pattern, and they don’t all lead to the same place. Some are best ruled out with a physician — there are medical causes that are important to consider. Others trace back to sleep itself. And the details — when it happens, how consistently — tend to matter in distinguishing between them.

Here are 3 reasons you might be waking up to pee at night, how to distinguish between them, and what to do so you can stay asleep through the night:

—Kat

P.S. I cover how to tell which of the 3 patterns yours might fall into — because the right next step depends on it.

Read more

Growth hormone (GH) is a peptide hormone released in pulses by the pituitary gland, a small endocrine gland located at the base of the brain.

In adults, GH plays several important roles in metabolism and body composition. It helps the body mobilize stored fat for energy (a process called lipolysis), supports the building and maintenance of proteins in tissues such as muscle, and participates in how the body processes carbohydrates and fats. GH also acts on multiple organs—including skeletal muscle, bone, and the liver—both directly and indirectly through another hormone called insulin-like growth factor-1 (IGF-1).

Because GH influences muscle maintenance, body composition, and metabolic regulation, it often appears in discussions about aging and longevity.

Growth hormone (GH) production gradually declines after early adulthood.

Physiological studies show that total daily GH output begins to fall in our 30s largely because the bursts of GH released become smaller.

In longevity circles, that observation is often interpreted in a linear way: GH decreases with age, so perhaps the solution is to increase GH again.

Yet major endocrine reviews and guideline statements have not endorsed raising GH as an anti-aging approach in otherwise healthy adults. Trials in older adults without GH deficiency have produced modest improvements in body composition but also higher rates of adverse effects, and there is no GH-raising therapy approved specifically for anti-aging.

The reason is that GH is not a single dial that can be turned up.

GH output emerges from a regulatory network in the brain involving multiple interacting inputs:

• growth hormone–releasing hormone (GHRH), which stimulates GH release

• somatostatin, which suppresses GH release

• ghrelin, which amplifies GH release

These inputs interact continuously with sleep depth, metabolic state, and reproductive hormones such as testosterone and estrogen.

So when GH changes across the lifespan, the more complete explanation lies in the upstream regulators.

In this article we will look at:

• what growth hormone–releasing hormone (GHRH) is and how it stimulates GH production

• the lesser-known role of GHRH as a sleep-promoting neuropeptide tied to deep sleep

• what tends to change after midlife in the sleep–GHRH–GH axis

• whether aging itself is the primary driver of those changes — or whether age is partly a proxy for modifiable factors

Let’s get started.

Subscribe now

Section 2. What is growth hormone–releasing hormone (GHRH), and why does it matter more than growth hormone itself?

Growth hormone–releasing hormone (GHRH) is the primary hypothalamic stimulator (a brain input) that promotes the release of growth hormone.

It is produced in a region of the brain called the hypothalamus, specifically in neurons located in the arcuate nucleus. From there, it travels through a specialized vascular network called the hypophyseal-portal circulation—a short blood vessel network that directly connects the hypothalamus and pituitary gland.

When GHRH reaches the pituitary gland, it binds to receptors on specialized cells called somatotrophs, the cells responsible for producing growth hormone.

Binding of GHRH to its receptor activates intracellular signaling pathways—primarily involving cyclic AMP and calcium—that both:

• increase GH gene expression and

• trigger the release of GH into the bloodstream.

Two under-discussed aspects of GHRH help explain why it plays a central role in GH physiology.

1. First, GHRH is not only a trigger for moment-to-moment GH release. It also supports the growth and maintenance of somatotroph cells themselves. Animal studies show that when GHRH activity is absent or impaired, the pituitary gland develops with fewer GH-producing cells—a condition known as anterior pituitary hypoplasia.

2. Second, GHRH production is itself tightly regulated by the body’s internal environment. Inputs related to energy, testosterone, estrogen, and metabolic status all influence how much GHRH is released.

Two of the important inhibitory influences are:

• somatostatin, another hypothalamic hormone that directly suppresses GH release

• insulin-like growth factor-1 (IGF-1), produced by tissues such as the liver in response to GH

These inputs create a feedback loop. As GH stimulates IGF-1 production in the body, IGF-1 feeds back to the brain to reduce GHRH activity and increase somatostatin, helping regulate future GH pulses.

Physiologically, GHRH therefore acts as part of a three-input architecture.

Somatostatin, produced in the hypothalamus, inhibits GH release and determines when GH pulses are suppressed.

Ghrelin, produced primarily in the stomach and also in the brain, amplifies GH release by activating the GHSR-1a receptor on pituitary cells.

Together these inputs organize GH release into pulses rather than continuous output.

The overall regulatory pattern looks like this:

• the hypothalamus releases GHRH, stimulating GH release

• the hypothalamus releases somatostatin, suppressing GH release

• the pituitary releases GH in pulses

• GH stimulates tissues such as the liver to produce IGF-1

• IGF-1 feeds back to reduce GHRH and increase somatostatin

This feedback architecture is why GH release remains pulsatile even when researchers experimentally supply GHRH continuously. The alternating hypothalamic inputs—particularly the timing of somatostatin inhibition—organize the pulse pattern.

Why does this matter?

Because GH physiology is organized around pulses rather than steady output.

A large GH pulse delivers a concentrated dose to tissues. Smaller or blunted pulses deliver less of that dose—even if total hormone exposure across the day is not hugely different.

In other words, the physiology depends not only on how much GH exists in the bloodstream, but on the timing and amplitude of the pulses themselves.

And that pattern turns out to be closely connected to sleep.

Section 3. Growth hormone–releasing hormone (GHRH) is also a sleep promoting neuropeptide

One of the more interesting aspects of GHRH physiology is that it does not only regulate growth hormone.

It also participates directly in the regulation of sleep.

Subscribe now

Across many species, administering GHRH increases non-REM sleep, particularly the deepest stage known as slow-wave sleep. Conversely, blocking endogenous GHRH activity—using antibodies or antagonists—reduces non-REM sleep and slow-wave activity.

Importantly, this effect does not appear to be explained by GH itself.

In animal studies, impairing GHRH activity produces chronically reduced non-REM sleep that cannot be restored by giving growth hormone. GHRH influences sleep through neural mechanisms that are partly independent of GH.

Experimental work suggests that GHRH can activate sleep-active neurons in brain regions involved in non-REM sleep regulation. When GHRH activity is blocked in these circuits, slow-wave activity decreases.

Human studies generally align with this pattern, although two variables appear to influence the results: how GHRH is delivered and the hormonal context of the individual.

In controlled experiments, episodic intravenous GHRH—given in pulses—tends to increase slow-wave sleep more than continuous infusion.

Average responses also differ somewhat between men and women. In men, peripheral GHRH administration has often been associated with increased slow-wave sleep and higher GH release. Studies including women show more variable effects, suggesting that sex-hormone context influences how the pathway behaves.

This dual role of growth hormone–releasing hormone (GHRH)—regulating both sleep depth and growth hormone (GH) release—helps explain a well-known feature of GH physiology: the largest GH pulse of the day usually occurs shortly after sleep begins.

The sequence often unfolds like this:

1. sleep onset

2. the first period of slow-wave sleep

3. increased hypothalamic GHRH activity and reduced somatostatin restraint

4. a large pituitary GH pulse

Deep sleep and GH release therefore track together because GHRH sits upstream of both processes.

This relationship raises the next important question.

Section 4. If growth hormone–releasing hormone (GHRH) helps organize both deep sleep and growth hormone (GH) pulses, what happens to this after midlife?

Two hypothalamic changes tend to appear together after midlife:

• reduced GHRH drive and/or reduced responsiveness to GHRH

• increased somatostatin restraint (somatostatin is the hypothalamic hormone that acts as the brake on GH release)

The downstream result: each GH pulse becomes smaller in amplitude.

This is what endocrinologists sometimes call the somatopause — not a shutdown of growth hormone, but a progressive reduction in pulse size, often cited at ~15% per decade after early adulthood.

Sleep architecture often changes in parallel.

Large meta-analyses of polysomnography recordings (overnight sleep studies that measure brainwaves, breathing, and movement) show that the percentage of slow-wave sleep decreases with age, while lighter sleep stages and nighttime awakenings increase. Because GHRH drives both GH pulses and deep sleep, these changes likely reflect the same hypothalamic changes — and reduced deep sleep, in turn, feeds back to further weaken the GH pulse.

Animal studies provide additional clues about the brain mechanisms involved.

• In aged female monkeys, direct sampling at the stalk–median eminence (the junction at the base of the brain where hypothalamic hormones enter the blood supply feeding the pituitary) showed reduced GHRH release along with higher baseline and pulse amplitude of somatostatin release compared with younger animals.

• In rodent studies, the number of neurons producing GHRH declines with age, while somatostatin neuron counts also change — suggesting an altered hypothalamic balance between stimulation and inhibition.

Human evidence is necessarily more indirect because hypothalamic peptides cannot easily be measured in living people. Instead, researchers examine GH pulse patterns and responses to experimental GHRH administration.

These studies support the same picture: aging-related reductions in GH release reflect both reduced GHRH drive and stronger somatostatin inhibition.

Taken together, this forms a loop: deep sleep supports GHRH activity, GHRH supports the GH pulse, and the GH pulse supports overnight processes like lipolysis (the breakdown of stored fat for energy) and protein synthesis. When any part of that loop weakens, the downstream output drops.

At first glance, this pattern is often attributed to aging.

But is this purely an aging story? Or is age partly acting as a proxy — a stand-in for factors that accumulate over time and influence sleep depth, GHRH neurons, and the balance between GHRH and somatostatin?

If the decline were purely about age, there wouldn’t be much to work with. But if age is tracking other variables — then those are inputs that can be influenced.

To answer that question, we need to look at what regulates GHRH activity in the first place.

Section 5. What else affects growth hormone–releasing hormone (GHRH) — beyond age?

Age correlates with lower GHRH-linked GH output, but GHRH neurons integrate multiple inputs that change independent of aging.

Several inputs are particularly influential:

• sleep pressure and sleep architecture

• circadian alignment

• reproductive hormones (testosterone and estrogen)

• metabolic status and energy balance

Many of these factors can change even before aging becomes a major factor, and they often change alongside it.

To understand how this plays out in practice, we need to examine how these inputs regulate GHRH activity:

1. Sleep pressure and sleep architecture

Slow-wave sleep—the deepest stage of non-REM sleep—is strongly shaped by what sleep researchers call sleep pressure.

Sleep pressure is the body’s built-in drive to sleep. The longer someone stays awake, the more this pressure builds. When sleep finally begins, that accumulated pressure expresses itself as deeper slow-wave sleep and larger slow-wave brain activity.

This matters for growth hormone because the largest GH pulses occur during deep non-REM sleep.

• When slow-wave sleep is strong, the conditions are more favorable for a large early-night GH pulse

• When sleep becomes fragmented—or when deep sleep becomes harder to generate—the GH pulse that normally accompanies it tends to become smaller.

Studies across both humans and animals show the same pattern. Sleep deprivation blunts the normal nocturnal GH surge, while recovery sleep—when deep sleep rebounds—often produces a stronger sleep-related GH pulse

2. Circadian alignment: when you sleep matters — even if how long you sleep doesn’t change

Sleep pressure determines how strongly the brain wants sleep, but circadian timing determines when the body expects sleep to occur.

The circadian rhythm is orchestrated by a small cluster of neurons in the hypothalamus called the suprachiasmatic nucleus (SCN). This structure acts as the brain’s internal clock, coordinating daily rhythms in sleep, body temperature, metabolism, and hormone release.

GH release is primarily linked to sleep onset and slow-wave sleep, but the circadian system modulates the hormonal environment in which that sleep-related pulse occurs.

Although sleep itself is the primary trigger for the large nightly GH pulse, the circadian clock modulates the hormonal environment in which that pulse occurs.

Classic studies of the sleep–GH relationship show that the first GH surge after sleep onset coincides with a period in which hypothalamic GHRH activity rises while somatostatin inhibition temporarily relaxes. The circadian clock helps create a window during which the sleep-triggered pulse can occur.

When sleep timing becomes misaligned with the internal clock—through irregular schedules or chronic circadian disruption—the hormonal environment that normally supports this pulse can weaken.

Circadian misalignment also influences glucose regulation and insulin sensitivity, both of which interact with the GH axis through hypothalamic and pituitary pathways. Hello

So even when sleep duration is unchanged, when sleep occurs relative to the internal clock can influence how endocrine rhythms behave.

Subscribe now

3. How testosterone and estrogen shape the growth hormone (GH) axis across the lifespan

Sex hormones also shape the growth hormone (GH) axis.

The best-documented example occurs during puberty, when rising sex-steroid levels are associated with a large increase in GH release. Much of this effect appears to come from increased pulse frequency and pulse amplitude.

In adult physiology, testosterone and estrogen influence the axis in somewhat different ways.

• Androgens, including testosterone, influence both GH secretion and the peripheral actions of GH.

• Estrogens are described as stimulating GH release while also altering how GH acts through the liver and other tissues. Experimental studies show that estrogen exposure can increase pituitary responsiveness to GHRH and reduce somatostatin inhibition.

Across midlife, the sex-hormone milieu often changes.

In men, testosterone levels and androgen signaling often decline or become more easily disrupted with age. In women, the transition through perimenopause and menopause produces more pronounced changes in estrogen and progesterone patterns.

Because these hormones interact with hypothalamic regulation, pituitary responsiveness, and sleep architecture, changes in the sex-steroid environment can influence GH pulsatility through multiple pathways.

4. How metabolic health influences the growth hormone (GH) axis

Energy balance is also an important regulator of the growth hormone (GH) axis.

Many of these effects act at the hypothalamic level—through hypothalamic regulation and pituitary responsiveness—not only through the pituitary gland’s capacity to produce GH.

Several metabolic patterns commonly observed in midlife illustrate this relationship.

• Visceral fat—the fat stored around abdominal organs—is consistently associated with lower GH release.

• In obesity, basal and pulsatile GH secretion tend to be reduced, while pulse frequency is often relatively preserved.

• Insulin and circulating fatty acids also influence the axis.

• High insulin levels can suppress GH release. In experimental settings, GH output can decrease within days of overfeeding as insulin rises. Cell-culture and animal studies also show that insulin can reduce the expression of genes involved in GH production and release.

• Free fatty acids exert a similar effect. Elevated fatty acid levels inhibit GH release, while lowering fatty acids—such as by temporarily suppressing fat breakdown—can increase GH responses during stimulation testing.

IGF-1 adds another dimension. IGF-1 is the hormone produced by tissues in response to GH, and it feeds back to the brain and pituitary to reduce GH drive through negative feedback.

In obesity, total IGF-1 often does not decline in parallel with GH, and free IGF-1 can even be higher, partly because insulin and IGF-binding proteins shift how much IGF-1 is bioavailable. This feedback can further suppress the hypothalamic inputs that drive GH pulses.

Taken together, several physiological changes that often appear with age—sleep fragmentation, increased visceral fat, higher insulin exposure, and altered testosterone and estrogen signaling—can all reshape the balance between GHRH stimulation and somatostatin inhibition.

From that perspective, chronological age often travels alongside these changes rather than acting as the only driver.

Section 6. Growth hormone (GH) gets the attention — but the factors that determine whether the nightly pulse still happens are within reach

Growth hormone tends to dominate longevity conversations, but it sits downstream in the physiology.

The question that matters is whether the conditions that allow a strong GH pulse are still present.

Each of the inputs we looked at — sleep depth, circadian timing, metabolic state, the sex-hormone environment — can change independently of the calendar. And each one feeds into the GHRH–somatostatin balance that determines pulse size.

Midlife GH decline often reflects the cumulative effect of several physiological inputs that change over time — many of which can be influenced.

None of those inputs ensure a larger GH pulse.

But they do shape the physiology that determines whether the pulse has the opportunity to occur.

And that opens a more constructive question for midlife and later life:

How can we support the conditions — sleep architecture, circadian alignment, metabolic health, and the hormonal environment — so that the brain and endocrine axis can continue running the nightly repair programs they were built to run?

When those conditions are supported, the physiology doesn’t need to be forced. Deep sleep, GHRH activity, and GH pulsatility can continue to function more favorably across midlife and later life — coordinating overnight restoration, maintenance, and metabolic regulation.

That’s the part of the growth hormone conversation that rarely gets discussed. And it’s within your influence.

—Kat

P.S. If your sleep feels less restorative than it used to — and you’re wondering which part of the equation is involved — my free 3AM Decoder maps 3am waking patterns across 5 patterns. It takes about 2 minutes:

3AM Decoder

References

• Cappola, A. R., Auchus, R. J., El-Hajj Fuleihan, G., Handelsman, D. J., Kalyani, R. R., McClung, M., Stuenkel, C. A., Thorner, M. O., & Verbalis, J. G. (2023). Hormones and aging: An Endocrine Society scientific statement. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1835–1874.

• U.S. Food and Drug Administration. (2020, September 1). FDA approves weekly therapy for adult growth hormone deficiency.

• Olarescu, N. C., Gunawardane, K., Hanson, T. K., Møller, N., & Jørgensen, J. O. L. (2025, April 18). Normal physiology of growth hormone in normal adults. In Endotext [Internet]

• Fredrick, J. R., Blackman, M. R., Corpas, E., Merriam, G. R., Kargi, A. Y., & Garcia, J. M. (2026, February 13). Growth hormone and aging. In Endotext [Internet].

• Stojilkovic, S. S. (2012). Molecular mechanisms of pituitary endocrine cell calcium handling. Cell Calcium, 51(3–4), 212–221.

• Mayo, K. E., Miller, T., DeAlmeida, V., Godfrey, P., Zheng, J., & Cunha, S. R. (2000). Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Progress in Hormone Research, 55, 237–266.

• Frohman, L. A., & Kineman, R. D. (2002). Growth hormone-releasing hormone and pituitary somatotrope proliferation. Minerva Endocrinologica, 27(4), 277–285.

• Obál, F., Jr., Kapás, L., Gardi, J., Taishi, P., Bodosi, B., & Krueger, J. M. (1999). Insulin-like growth factor-1 (IGF-1)-induced inhibition of growth hormone secretion is associated with sleep suppression. Brain Research, 818(2), 267–274.

• Hulse, J. A., Rosenthal, S. M., Cuttler, L., Kaplan, S. L., & Grumbach, M. M. (1986). The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men. The Journal of Clinical Endocrinology & Metabolism, 63(4), 872–878.

• Obal, F., Jr., & Krueger, J. M. (2004). GHRH and sleep. Sleep Medicine Reviews, 8(5), 367–377.

• Marshall, L., Mölle, M., Böschen, G., Steiger, A., Fehm, H. L., & Born, J. (1996). Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). The Journal of Clinical Endocrinology & Metabolism, 81(3), 1009–1013.

• Van Cauter, E., & Plat, L. (1996). Physiology of growth hormone secretion during sleep. The Journal of Pediatrics, 128(5 Pt 2), S32–S37.

• Russell-Aulet, M., Dimaraki, E. V., Jaffe, C. A., DeMott-Friberg, R., & Barkan, A. L. (2001). Aging-related growth hormone (GH) decrease is a selective hypothalamic GH-releasing hormone pulse amplitude mediated phenomenon. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 56(2), M124–M129.

• Ohayon, M. M., Carskadon, M. A., Guilleminault, C., & Vitiello, M. V. (2004). Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. Sleep, 27(7), 1255–1273.

• Brandenberger, G., Gronfier, C., Chapotot, F., Simon, C., & Piquard, F. (2000). Effect of sleep deprivation on overall 24 h growth-hormone secretion. The Lancet, 356(9239), 1408. h

• Clasey, J. L., Weltman, A., Patrie, J., Weltman, J. Y., Pezzoli, S., Bouchard, C., Thorner, M. O., & Hartman, M. L. (2001). Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. The Journal of Clinical Endocrinology & Metabolism, 86(8), 3845–3852.

• Morris, C. J., Aeschbach, D., & Scheer, F. A. J. L. (2012). Circadian system, sleep and endocrinology. Molecular and Cellular Endocrinology, 349(1), 91–104.

• Mauras, N., Blizzard, R. M., Link, K., Johnson, M. L., Rogol, A. D., & Veldhuis, J. D. (1987). Augmentation of growth hormone secretion during puberty: Evidence for a pulse amplitude-modulated phenomenon. The Journal of Clinical Endocrinology & Metabolism, 64(3), 596–601.

Read more